2127 lines
316 KiB
Text
2127 lines
316 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK1401">
|
|
<meta name="ncbi_domain" content="gene">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK1401/?report=reader">
|
|
<meta name="ncbi_pagename" content="Fanconi Anemia - GeneReviews® - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Fanconi Anemia - GeneReviews® - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/gene/porphyria-ct/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/gene/fahn/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/gene/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="GeneReviews® [Internet]">
|
|
<meta name="citation_title" content="Fanconi Anemia">
|
|
<meta name="citation_publisher" content="University of Washington, Seattle">
|
|
<meta name="citation_date" content="2021/06/03">
|
|
<meta name="citation_author" content="Parinda A Mehta">
|
|
<meta name="citation_author" content="Christen Ebens">
|
|
<meta name="citation_pmid" content="20301575">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1401/">
|
|
<meta name="citation_keywords" content="Fanconi Pancytopenia">
|
|
<meta name="citation_keywords" content="Fanconi Pancytopenia">
|
|
<meta name="citation_keywords" content="Breast cancer type 1 susceptibility protein">
|
|
<meta name="citation_keywords" content="Breast cancer type 2 susceptibility protein">
|
|
<meta name="citation_keywords" content="DNA repair endonuclease XPF">
|
|
<meta name="citation_keywords" content="DNA repair protein RAD51 homolog 1">
|
|
<meta name="citation_keywords" content="DNA repair protein RAD51 homolog 3">
|
|
<meta name="citation_keywords" content="DNA repair protein XRCC2">
|
|
<meta name="citation_keywords" content="E3 ubiquitin-protein ligase FANCL">
|
|
<meta name="citation_keywords" content="E3 ubiquitin-protein ligase RFWD3">
|
|
<meta name="citation_keywords" content="Fanconi anemia core complex-associated protein 100">
|
|
<meta name="citation_keywords" content="Fanconi anemia group A protein">
|
|
<meta name="citation_keywords" content="Fanconi anemia group B protein">
|
|
<meta name="citation_keywords" content="Fanconi anemia group C protein">
|
|
<meta name="citation_keywords" content="Fanconi anemia group D2 protein">
|
|
<meta name="citation_keywords" content="Fanconi anemia group E protein">
|
|
<meta name="citation_keywords" content="Fanconi anemia group F protein">
|
|
<meta name="citation_keywords" content="Fanconi anemia group G protein">
|
|
<meta name="citation_keywords" content="Fanconi anemia group I protein">
|
|
<meta name="citation_keywords" content="Fanconi anemia group J protein">
|
|
<meta name="citation_keywords" content="Fanconi anemia group M protein">
|
|
<meta name="citation_keywords" content="Mitotic spindle assembly checkpoint protein MAD2B">
|
|
<meta name="citation_keywords" content="Partner and localizer of BRCA2">
|
|
<meta name="citation_keywords" content="Structure-specific endonuclease subunit SLX4">
|
|
<meta name="citation_keywords" content="Ubiquitin-conjugating enzyme E2 T">
|
|
<meta name="citation_keywords" content="BRCA1">
|
|
<meta name="citation_keywords" content="BRCA2">
|
|
<meta name="citation_keywords" content="BRIP1">
|
|
<meta name="citation_keywords" content="ERCC4">
|
|
<meta name="citation_keywords" content="FAAP100">
|
|
<meta name="citation_keywords" content="FANCA">
|
|
<meta name="citation_keywords" content="FANCB">
|
|
<meta name="citation_keywords" content="FANCC">
|
|
<meta name="citation_keywords" content="FANCD2">
|
|
<meta name="citation_keywords" content="FANCE">
|
|
<meta name="citation_keywords" content="FANCF">
|
|
<meta name="citation_keywords" content="FANCG">
|
|
<meta name="citation_keywords" content="FANCI">
|
|
<meta name="citation_keywords" content="FANCL">
|
|
<meta name="citation_keywords" content="FANCM">
|
|
<meta name="citation_keywords" content="MAD2L2">
|
|
<meta name="citation_keywords" content="PALB2">
|
|
<meta name="citation_keywords" content="RAD51">
|
|
<meta name="citation_keywords" content="RAD51C">
|
|
<meta name="citation_keywords" content="RFWD3">
|
|
<meta name="citation_keywords" content="SLX4">
|
|
<meta name="citation_keywords" content="UBE2T">
|
|
<meta name="citation_keywords" content="XRCC2">
|
|
<meta name="citation_keywords" content="Fanconi Anemia">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Fanconi Anemia">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="University of Washington, Seattle">
|
|
<meta name="DC.Contributor" content="Parinda A Mehta">
|
|
<meta name="DC.Contributor" content="Christen Ebens">
|
|
<meta name="DC.Date" content="2021/06/03">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1401/">
|
|
<meta name="description" content="Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.">
|
|
<meta name="og:title" content="Fanconi Anemia">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1401/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/gene/fa/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1401/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8BA69F7C85549100000000011800E4.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK1401/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/gene/porphyria-ct/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Fanconi Anemia</div><div class="j">GeneReviews® [Internet]</div></div><div class="tail"><a href="/books/n/gene/fahn/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK1401/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK1401/&text=Fanconi%20Anemia"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/gene/?report=reader">Title Information</a><a href="/books/n/gene/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK1401/?report=classic">Switch to classic view</a><a href="/books/NBK1401/pdf/Bookshelf_NBK1401.pdf">PDF (716K)</a><a href="/books/NBK1401/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK1401%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8BA69F7C85549100000000011800E4.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK1401_"><span class="title" itemprop="name">Fanconi Anemia</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: Fanconi Pancytopenia</div><p class="contribs">Mehta PA, Ebens C.</p><p class="fm-aai"><a href="#_NBK1401_pubdet_">Publication Details</a></p><p><em>Estimated reading time: 52 minutes</em></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="fa.Summary" itemprop="description"><h2 id="_fa_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of FA is established in a proband with increased chromosome breakage and radial forms on cytogenetic testing of lymphocytes with diepoxybutane (DEB) and mitomycin C (MMC) and/or one of the following identified on molecular genetic testing: biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA; a heterozygous pathogenic variant in <i>RAD51</i> known to cause autosomal dominant FA; or a hemizygous pathogenic variant in <i>FANCB</i> known to cause X-linked FA.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Administration of oral androgens (e.g., oxymetholone) improves blood counts (red cell and platelets) in approximately 50% of individuals with FA; granulocyte colony-stimulating factor improves the neutrophil count in some individuals; hematopoietic stem cell transplantation (HSCT) is the only curative therapy for the hematologic manifestations of FA, but the high risk for solid tumors remains and may even be increased in those undergoing HSCT. All these treatments have potential significant toxicity. early detection and surgical removal remains the mainstay of therapy for solid tumors. Treatment of growth deficiency, limb anomalies, ocular anomalies, renal malformations, genital anomalies, hypothyroidism, cardiac anomalies, and dermatologic manifestations as recommended by the subspecialty care provider. Hearing aids may be helpful for hearing loss as per otolaryngologist; supplemental feeding as needed by nasogastric tube or gastrostomy; vitamin D supplementation; early intervention for developmental delays; individualized education plan for school-age children; speech, occupational, and physical therapy as needed; liberal use of sunscreen and rash guards; social work and care coordination as needed.</p><p><i>Prevention of primary manifestations:</i> Human papilloma virus (HPV) vaccination to reduce the risk for gynecologic cancer in females, and possibly reduce the risk of oral cancer in all individuals.</p><p><i>Prevention of secondary complications:</i> T-cell depletion of the donor graft to minimize the risk of graft-vs-host disease; conditioning regimen without radiation prior to HSCT to reduce the subsequent risk of developing solid tumors.</p><p><i>Surveillance:</i> Clinical assessment of growth, feeding, nutrition, spine, and ocular issues at each visit throughout childhood. Annual ophthalmology examination; annual evaluation with endocrinologist including TSH, free T4, 25-hydroxy vitamin D, two-hour glucose tolerance testing, and insulin levels; assessment of pubertal stage and hormone levels at puberty and every two years until puberty is complete; follow up hearing evaluation if exposed to ototoxic drugs; annual developmental assessment; blood counts every three to four months or as needed; bone marrow aspirate and biopsy to evaluate morphology and cellularity, FISH and cytogenetics to evaluate for emergence of a malignant clone at least annually after age two years; liver function tests every three to six months and liver ultrasound examination every six to twelve months in those receiving androgen therapy; gynecologic assessment for genital lesions annually beginning at age 13 years; vulvo-vaginal examinations and Pap smear annually beginning at age 18 years; oral examinations for tumors every six months beginning at age nine to ten years; annual nasolaryngoscopy beginning at age ten years; dermatology evaluation every six to 12 months; annual abdominal ultrasound and brain MRI in those with <i>BRCA2</i>-related FA. Additional cancer surveillance for individuals with <i>BRCA1-</i>, <i>BRCA2-</i>, <i>PALB2-</i>, <i>BRIP1-,</i> and <i>RAD51C-</i>related FA.</p><p><i>Agents/circumstances to avoid:</i> Transfusions of red cells or platelets for persons who are candidates for HSCT; family members as blood donors if HSCT is being considered; blood products that are not filtered (leukodepleted) or irradiated; toxic agents that have been implicated in tumorigenesis; unsafe sex practices, which increase the risk of HPV-associated malignancy; excessive sun exposure. Radiographic studies solely for the purpose of surveillance (i.e., in the absence of clinical indications) should be minimized.</p><p><i>Evaluation of relatives at risk:</i> DEB/MMC testing or molecular genetic testing (if the family-specific pathogenic variants are known) of all sibs of a proband for early diagnosis, treatment, and monitoring for physical abnormalities, bone marrow failure, and related cancers.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Fanconi anemia (FA) can be inherited in an autosomal recessive manner, an autosomal dominant manner (<i>RAD51</i>-related FA), or an X-linked manner (<i>FANCB</i>-related FA).</p><p><i>Autosomal recessive FA:</i> Each sib of an affected individual has a 25% chance of inheriting both pathogenic variants and being affected, a 50% chance of inheriting one pathogenic variant and being a heterozygote, and a 25% chance of inheriting neither of the familial FA-related pathogenic variants. Heterozygotes are not at risk for autosomal recessive FA. However, heterozygous mutation of a subset of FA-related genes (e.g., <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, <i>BRIP1,</i> and <i>RAD51C</i>) is associated with an increased risk for breast and other cancers.</p><p><i>Autosomal dominant FA:</i> Given that all affected individuals with <i>RAD51</i>-related FA reported to date have the disorder as a result of a <i>de novo RAD51</i> pathogenic variant, the risk to other family members is presumed to be low.</p><p><i>X-linked FA:</i> For carrier females the chance of transmitting the pathogenic variant in each pregnancy is 50%; males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will be carriers and will usually not be affected.</p><p>Carrier testing for at-risk relatives (for autosomal recessive and X-linked FA) and prenatal and preimplantation genetic testing are possible if the pathogenic variant(s) in the family are known.</p></div></div><div id="fa.Diagnosis"><h2 id="_fa_Diagnosis_">Diagnosis</h2><p>Recommendations for diagnosis were agreed upon at a 2013 consensus conference (see <a href="https://www.fanconi.org/explore/clinical-care-guidelines" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi Anemia Clinical Care Guidelines</a>, 2020 edition).</p><div id="fa.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Fanconi anemia (FA) <b>should be suspected</b> in individuals with the following clinical and laboratory features.</p><p><b>Physical features</b> (in ~75% of affected persons)</p><ul><li class="half_rhythm"><div>Prenatal and/or postnatal short stature</div></li><li class="half_rhythm"><div>Abnormal skin pigmentation (e.g., café au lait macules, hypopigmentation)</div></li><li class="half_rhythm"><div>Skeletal malformations (e.g., hypoplastic thumb, hypoplastic radius)</div></li><li class="half_rhythm"><div>Microcephaly</div></li><li class="half_rhythm"><div>Ophthalmic anomalies</div></li><li class="half_rhythm"><div>Genitourinary tract anomalies</div></li></ul><p>
|
|
<b>Laboratory findings</b>
|
|
</p><ul><li class="half_rhythm"><div>Macrocytosis</div></li><li class="half_rhythm"><div>Increased fetal hemoglobin (often precedes anemia)</div></li><li class="half_rhythm"><div>Cytopenia (especially thrombocytopenia, leukopenia, and neutropenia)</div></li></ul><p>
|
|
<b>Pathology findings</b>
|
|
</p><ul><li class="half_rhythm"><div>Progressive bone marrow failure</div></li><li class="half_rhythm"><div>Adult-onset aplastic anemia</div></li><li class="half_rhythm"><div>Myelodysplastic syndrome (MDS)</div></li><li class="half_rhythm"><div>Acute myelogenous leukemia (AML)</div></li><li class="half_rhythm"><div>Early-onset solid tumors (e.g., squamous cell carcinomas of the head and neck, esophagus, and vulva; cervical cancer; liver tumors)</div></li><li class="half_rhythm"><div>Inordinate toxicities from chemotherapy or radiation</div></li></ul></div><div id="fa.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of FA <b>is established</b> in a proband with either of the following:</p><ul><li class="half_rhythm"><div class="half_rhythm">Increased chromosome breakage and radial forms on cytogenetic testing of lymphocytes with diepoxybutane (DEB) and mitomycin C (MMC).</div><div class="half_rhythm">Note: (1) The background rate of chromosome breakage in control chromosomes is more variable with MMC; thus, some centers use DEB while other centers use both DEB and MMC. (2) If results of lymphocyte testing are normal or inconclusive and mosaicism is suspected, testing can be performed on an alternative cell type, such as skin fibroblasts. See <a href="https://www.fanconi.org/explore/clinical-care-guidelines" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi Anemia Clinical Care Guidelines</a>.</div></li><li class="half_rhythm"><div class="half_rhythm">Identification of biallelic pathogenic (or likely pathogenic) variants in one of the 21 genes known to cause autosomal recessive FA, or a heterozygous pathogenic (or likely pathogenic) variant in <i>RAD51</i> known to cause autosomal dominant FA, or a hemizygous pathogenic (or likely pathogenic) variant in <i>FANCB</i> known to cause X-linked FA (see <a href="/books/NBK1401/table/fa.T.molecular_genetic_testing_used_in_f/?report=objectonly" target="object" rid-ob="figobfaTmoleculargenetictestingusedinf">Table 1</a>)</div></li></ul><p>Note: (1) Per ACMG/AMP variant interpretation guidelines, the terms "pathogenic variant" and "likely pathogenic variant" are synonymous in a clinical setting, meaning that both are considered diagnostic and can be used for clinical decision making [<a class="bibr" href="#fa.REF.richards.2015.405" rid="fa.REF.richards.2015.405">Richards et al 2015</a>]. Reference to "pathogenic variants" in this <i>GeneReview</i> is understood to include likely pathogenic variants. (2) The identification of variant(s) of uncertain significance cannot be used to confirm or rule out the diagnosis.</p><p>Molecular testing approaches can include <b>single-gene testing</b>, use of a <b>multigene panel</b>, and <b>more comprehensive</b>
|
|
<b>genomic testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-gene testing.</b> Sequence analysis of <i>FANCA</i> can be performed first to detect missense, nonsense, and splice site variants and small intragenic deletions/insertions. Note: Depending on the sequencing method used, single-exon, multiexon, or whole-gene deletions/duplications may not be detected. If only one or no variant is detected by the sequencing method used, the next step is to perform gene-targeted deletion/duplication analysis to detect exon and whole-gene deletions or duplications.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A multigene panel</b> that includes the genes in <a href="/books/NBK1401/table/fa.T.molecular_genetic_testing_used_in_f/?report=objectonly" target="object" rid-ob="figobfaTmoleculargenetictestingusedinf">Table 1</a> and other genes of interest (see <a href="#fa.Differential_Diagnosis">Differential Diagnosis</a>) may be considered next if single-gene testing does not identify a <i>FANCA</i> pathogenic variant. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel provides the best opportunity to identify the genetic cause of the condition while limiting identification of pathogenic variants in genes that do not explain the underlying phenotype. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/?report=reader#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/?report=reader#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive genomic testing</b> (when available) including <b>exome sequencing</b> and <b>genome sequencing</b> may be considered if single-gene testing (and/or use of a multigene panel) fails to confirm a diagnosis in an individual with features of Fanconi anemia. Such testing may provide or suggest a diagnosis not previously considered (e.g., pathogenic variant[s] in a different gene or genes that results in a similar clinical presentation).</div><div class="half_rhythm">For an introduction to comprehensive genomic testing click <a href="/books/n/gene/app5/?report=reader#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/?report=reader#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figfaTmoleculargenetictestingusedinf"><a href="/books/NBK1401/table/fa.T.molecular_genetic_testing_used_in_f/?report=objectonly" target="object" title="Table 1. " class="img_link icnblk_img" rid-ob="figobfaTmoleculargenetictestingusedinf"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="fa.T.molecular_genetic_testing_used_in_f"><a href="/books/NBK1401/table/fa.T.molecular_genetic_testing_used_in_f/?report=objectonly" target="object" rid-ob="figobfaTmoleculargenetictestingusedinf">Table 1. </a></h4><p class="float-caption no_bottom_margin">Molecular Genetic Testing Used in Fanconi Anemia </p></div></div></div></div><div id="fa.Clinical_Characteristics"><h2 id="_fa_Clinical_Characteristics_">Clinical Characteristics</h2><div id="fa.Clinical_Description"><h3>Clinical Description</h3><p>The primary clinical features of Fanconi anemia (FA) include physical features, progressive bone marrow failure manifest as pancytopenia, and cancer susceptibility; however, some individuals with FA have neither physical abnormalities nor bone marrow failure.</p><div id="fa.Physical_Findings"><h4>Physical Findings</h4><p>Physical features occur in approximately 75% of individuals with FA.</p><ul><li class="half_rhythm"><div>Growth deficiency. Prenatal and/or postnatal short stature, low birth weight</div></li><li class="half_rhythm"><div>Abnormal skin pigmentation (40%). Generalized hyperpigmentation; café au lait macules, hypopigmentation</div></li><li class="half_rhythm"><div>Skeletal malformations of upper limbs, unilateral or bilateral (35%):</div><ul><li class="half_rhythm"><div>Thumbs (35%). Absent, hypoplastic, bifid, duplicated, triphalangeal, long, proximally placed</div></li><li class="half_rhythm"><div>Radii (7%). Absent or hypoplastic (only with abnormal thumbs), absent or weak pulse</div></li><li class="half_rhythm"><div>Hands (5%). Flat thenar eminence, absent first metacarpal, clinodactyly, polydactyly</div></li><li class="half_rhythm"><div>Ulnae (1%). Dysplastic, short</div></li></ul></li><li class="half_rhythm"><div>Skeletal malformations of lower limbs (5%):</div><ul><li class="half_rhythm"><div>Syndactyly, abnormal toes, club feet</div></li><li class="half_rhythm"><div>Congenital hip dislocation</div></li></ul></li><li class="half_rhythm"><div>Microcephaly (20%)</div></li><li class="half_rhythm"><div>Ophthalmic (20%). Microphthalmia, cataracts, astigmatism, strabismus, epicanthal folds, hypotelorism, hypertelorism, ptosis</div></li><li class="half_rhythm"><div>Genitourinary tract anomalies:</div><ul><li class="half_rhythm"><div class="half_rhythm">Renal (20%). Horseshoe, ectopic, pelvic, hypoplastic, dysplastic, or absent kidney; hydronephrosis or hydroureter</div></li><li class="half_rhythm"><div class="half_rhythm">Males (25%). Hypospadias, micropenis, cryptorchidism, anorchia, hypo- or azoospermia, reduced fertility</div></li><li class="half_rhythm"><div class="half_rhythm">Females (2%). Bicornuate or uterus malposition, small ovaries</div><div class="half_rhythm">Note: Pregnancy is possible in females, whether or not they have undergone hematopoietic stem cell transplantation (HSCT).</div></li></ul></li><li class="half_rhythm"><div>Endocrine disorders (50%-75%). Hypothyroidism (30%-60%), diabetes (8%-10%), hyperglycemia / impaired glucose tolerance (25%-70%), and insulin resistance [<a class="bibr" href="#fa.REF.petryk.2015.803" rid="fa.REF.petryk.2015.803">Petryk et al 2015</a>]</div></li><li class="half_rhythm"><div>Hearing loss (10%). Usually conductive secondary to middle-ear bony anomalies with or without additional ear anomalies (e.g., dysplastic auricle, narrow ear canal, abnormal pinna)</div></li><li class="half_rhythm"><div>Congenital heart defect (6%). Patent ductus arteriosus, atrial septal defect, ventricular septal defect, coarctation of the aorta, truncus arteriosus, situs inversus</div></li><li class="half_rhythm"><div>Gastrointestinal (5%). Esophageal, duodenal, or jejunal atresia, imperforate anus, tracheoesophageal fistula, annular pancreas, malrotation</div></li><li class="half_rhythm"><div>Central nervous system (3%). Small pituitary, pituitary stalk interruption syndrome, absent corpus callosum, cerebellar hypoplasia, hydrocephalus, dilated ventricles</div></li><li class="half_rhythm"><div>Other:</div><ul><li class="half_rhythm"><div>Facial features (2%). Triangular face shape, micrognathia, mid-face hypoplasia</div></li><li class="half_rhythm"><div>Spine anomalies (2%). Spina bifida, scoliosis, hemivertebrae, rib anomalies, coccygeal aplasia</div></li><li class="half_rhythm"><div>Neck anomalies (1%). Sprengel deformity, Klippel-Feil anomaly, short or webbed neck, low hairline</div></li></ul></li></ul><p>Note: Percentages are calculated from 2,000 individuals reported in the literature from 1927 to 2014. Frequencies are approximate, since many reports did not mention physical descriptions.</p></div><div id="fa.Developmental_Delay__Intellectual_Dis"><h4>Developmental Delay / Intellectual Disability</h4><p>Developmental delay and/or intellectual disability is seen in 10%.</p></div><div id="fa.Bone_Marrow_Failure"><h4>Bone Marrow Failure</h4><p>The age of onset of bone marrow failure is highly variable, even among sibs. An analysis of 754 individuals with pathogenic variants in <i>FANCA</i>, <i>FANCC</i>, and <i>FANCG</i> identified an average age of onset of 7.6 years. Rarely, bone marrow failure can present in infants and small children [<a class="bibr" href="#fa.REF.shimamura.2010.101" rid="fa.REF.shimamura.2010.101">Shimamura & Alter 2010</a>]. The risk of developing any hematologic abnormality is 90% by age 40 years [<a class="bibr" href="#fa.REF.kutler.2003.1249" rid="fa.REF.kutler.2003.1249">Kutler et al 2003</a>].</p><ul><li class="half_rhythm"><div>Thrombocytopenia or leukopenia usually precede anemia. These are commonly associated with macrocytosis and elevated fetal hemoglobin.</div></li><li class="half_rhythm"><div>Pancytopenia generally worsens over time.</div></li><li class="half_rhythm"><div>Sweet syndrome (neutrophilic skin infiltration) was associated with progression of hematologic disease in six of seven individuals with FA [<a class="bibr" href="#fa.REF.giulino.2011.278" rid="fa.REF.giulino.2011.278">Giulino et al 2011</a>].</div></li><li class="half_rhythm"><div>The severity of bone marrow failure can be classified by the degree of cytopenia(s) (<a href="/books/NBK1401/table/fa.T.severity_of_bone_marrow_failure_in/?report=objectonly" target="object" rid-ob="figobfaTseverityofbonemarrowfailurein">Table 2</a>). Importantly, to meet these criteria for marrow failure, the cytopenias must be persistent and unexplained by other causes.</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figfaTseverityofbonemarrowfailurein"><a href="/books/NBK1401/table/fa.T.severity_of_bone_marrow_failure_in/?report=objectonly" target="object" title="Table 2. " class="img_link icnblk_img" rid-ob="figobfaTseverityofbonemarrowfailurein"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="fa.T.severity_of_bone_marrow_failure_in"><a href="/books/NBK1401/table/fa.T.severity_of_bone_marrow_failure_in/?report=objectonly" target="object" rid-ob="figobfaTseverityofbonemarrowfailurein">Table 2. </a></h4><p class="float-caption no_bottom_margin">Severity of Bone Marrow Failure in Fanconi Anemia </p></div></div></div><div id="fa.Cancer_Susceptibility"><h4>Cancer Susceptibility</h4><p><b>Acute myelogenous leukemia</b>
|
|
<b>(AML).</b> The relative risk for AML is increased approximately 500-fold [<a class="bibr" href="#fa.REF.rosenberg.2008.511" rid="fa.REF.rosenberg.2008.511">Rosenberg et al 2008</a>, <a class="bibr" href="#fa.REF.alter.2010.179" rid="fa.REF.alter.2010.179">Alter et al 2010</a>, <a class="bibr" href="#fa.REF.tamary.2010.1300" rid="fa.REF.tamary.2010.1300">Tamary et al 2010</a>]. In a competing risk analysis of the combined cohorts, the cumulative incidence of AML was 13% by age 50 years, with most individuals diagnosed between ages 15 and 35 years.</p><p>An increased risk of developing myelodysplastic syndrome (MDS)/AML is associated with monosomy 7 and most 7q deletions. Clonal amplifications of chromosome 3q26-q29 were reported in association with an increased risk of progression to MDS/AML [<a class="bibr" href="#fa.REF.neitzel.2007" rid="fa.REF.neitzel.2007">Neitzel et al 2007</a>, <a class="bibr" href="#fa.REF.mehta.2010.180" rid="fa.REF.mehta.2010.180">Mehta et al 2010</a>].</p><p><b>Solid tumors</b> may be the first manifestation of FA in individuals who have no birth defects and have not experienced bone marrow failure.</p><ul><li class="half_rhythm"><div>Head and neck squamous cell carcinomas (HNSCCs) are the most common solid tumor in individuals with FA. The incidence is 500- to 700-fold higher than in the general population. The HNSCCs in FA show distinct differences from HNSCCs seen in the general population. HNSCCs:</div><ul><li class="half_rhythm"><div>Occur at an earlier age (20-40 years) than in the general population;</div></li><li class="half_rhythm"><div>Most commonly occur in the oral cavity (e.g., tongue);</div></li><li class="half_rhythm"><div>Present at an advanced stage;</div></li><li class="half_rhythm"><div>Respond poorly to therapy.</div></li></ul></li><li class="half_rhythm"><div>Individuals with FA are at increased risk for second primary cancers of the skin and genitourinary tract. The pattern of second primaries resembles that observed in HPV-associated HNSCCs in the general population [<a class="bibr" href="#fa.REF.morris.2011.739" rid="fa.REF.morris.2011.739">Morris et al 2011</a>].</div></li><li class="half_rhythm"><div>Individuals with FA receiving androgen treatment for bone marrow failure are also at increased risk for liver tumors.</div></li></ul></div></div><div id="fa.Phenotype_Correlations_by_Gene"><h3>Phenotype Correlations by Gene</h3><p><b><i>BRCA2</i>.</b> Biallelic pathogenic variants in <i>BRCA2</i> are associated with early-onset acute leukemia and solid tumors [<a class="bibr" href="#fa.REF.hirsch.2004.2554" rid="fa.REF.hirsch.2004.2554">Hirsch et al 2004</a>, <a class="bibr" href="#fa.REF.wagner.2004.3226" rid="fa.REF.wagner.2004.3226">Wagner et al 2004</a>, <a class="bibr" href="#fa.REF.myers.2012.462" rid="fa.REF.myers.2012.462">Myers et al 2012</a>]. The cumulative probability of any malignancy was 97% by age six years, including AML, medulloblastoma, and Wilms tumor [<a class="bibr" href="#fa.REF.alter.2007.1" rid="fa.REF.alter.2007.1">Alter et al 2007</a>].</p><p><b><i>FANCB</i>.</b> More recently <i>FANCB</i> pathogenic variants are shown to predominantly cause early-onset bone marrow failure and severe congenital abnormalities. Biochemical and cell-based assays of causative variants reveal functional properties of <i>FANCB</i> that are associated with clinical severity [<a class="bibr" href="#fa.REF.jung.2020.1588" rid="fa.REF.jung.2020.1588">Jung et al 2020</a>].</p><p><b><i>FANCG</i>.</b> Pathogenic variants in <i>FANCG</i> may be associated with severe marrow failure and a higher incidence of leukemia than <i>FANCC</i> [<a class="bibr" href="#fa.REF.faivre.2000.4064" rid="fa.REF.faivre.2000.4064">Faivre et al 2000</a>].</p><p><b><i>PALB2.</i></b> Solid tumors (e.g., medulloblastoma, Wilms tumor) are associated with <i>PALB2</i> pathogenic variants [<a class="bibr" href="#fa.REF.reid.2007.162" rid="fa.REF.reid.2007.162">Reid et al 2007</a>].</p></div><div id="fa.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>The clinical spectrum of FA remains heterogenous. There are no clear-cut genotype-phenotype correlations. In general, null variants lead to a more severe phenotype (e.g., congenital anomalies, early-onset bone marrow failure, and MDS/AML) than hypomorphic variants. A literature review of genotype-phenotype associations in Fanconi anemia was recently published [<a class="bibr" href="#fa.REF.fiescoroa.2019.100589" rid="fa.REF.fiescoroa.2019.100589">Fiesco-Roa et al 2019</a>].</p><p><b><i>BRCA2</i>.</b> All persons with an IVS7 pathogenic variant in <i>BRCA2</i> developed AML by age three years; those with other <i>BRCA2</i> pathogenic variants who developed AML did so by age six years [<a class="bibr" href="#fa.REF.alter.2006.446" rid="fa.REF.alter.2006.446">Alter 2006</a>].</p><p><b><i>FANCA</i>.</b> Conflicting reports have associated [<a class="bibr" href="#fa.REF.faivre.2000.4064" rid="fa.REF.faivre.2000.4064">Faivre et al 2000</a>] and refuted association [<a class="bibr" href="#fa.REF.castella.2011.3759" rid="fa.REF.castella.2011.3759">Castella et al 2011</a>] of homozygous <i>FANCA</i> null pathogenic variants with earlier-onset anemia and higher incidence of leukemia than individuals with pathogenic variants that permit production of an abnormal FANCA protein. Other <i>FANCA</i> variants (<a href="/books/NBK1401/table/fa.T.fanconi_anemia_notable_pathogenic_v/?report=objectonly" target="object" rid-ob="figobfaTfanconianemianotablepathogenicv">p.His913Pro</a>, <a href="/books/NBK1401/table/fa.T.fanconi_anemia_notable_pathogenic_v/?report=objectonly" target="object" rid-ob="figobfaTfanconianemianotablepathogenicv">p.Arg951Gln</a>, <a href="/books/NBK1401/table/fa.T.fanconi_anemia_notable_pathogenic_v/?report=objectonly" target="object" rid-ob="figobfaTfanconianemianotablepathogenicv">p.Arg951Trp</a>) have been associated with slower hematologic disease progression [<a class="bibr" href="#fa.REF.bottega.2018.417" rid="fa.REF.bottega.2018.417">Bottega et al 2018</a>].</p><p><b><i>FANCB</i>.</b> Truncating variants often present with VACTERL-H [<a class="bibr" href="#fa.REF.mccauley.2011.2370" rid="fa.REF.mccauley.2011.2370">McCauley et al 2011</a>].</p><p>
|
|
<b>
|
|
<i>FANCC</i>
|
|
</b>
|
|
</p><ul><li class="half_rhythm"><div><a href="/books/NBK1401/table/fa.T.fanconi_anemia_notable_pathogenic_v/?report=objectonly" target="object" rid-ob="figobfaTfanconianemianotablepathogenicv">c.456+4A>T</a>, <a href="/books/NBK1401/table/fa.T.fanconi_anemia_notable_pathogenic_v/?report=objectonly" target="object" rid-ob="figobfaTfanconianemianotablepathogenicv">p.Arg548Ter</a>, and <a href="/books/NBK1401/table/fa.T.fanconi_anemia_notable_pathogenic_v/?report=objectonly" target="object" rid-ob="figobfaTfanconianemianotablepathogenicv">p.Leu554Pro</a> are associated with earlier onset of hematologic abnormalities and more severe congenital anomalies than other pathogenic variants, such as <a href="/books/NBK1401/table/fa.T.fanconi_anemia_notable_pathogenic_v/?report=objectonly" target="object" rid-ob="figobfaTfanconianemianotablepathogenicv">c.67delG</a> [<a class="bibr" href="#fa.REF.faivre.2005.55" rid="fa.REF.faivre.2005.55">Faivre et al 2005</a>]. However modifiers play a role as the c.456+4A>T variant in Japanese individuals results in a milder phenotype [<a class="bibr" href="#fa.REF.futaki.2000.1493" rid="fa.REF.futaki.2000.1493">Futaki et al 2000</a>]</div></li><li class="half_rhythm"><div><a href="/books/NBK1401/table/fa.T.fanconi_anemia_notable_pathogenic_v/?report=objectonly" target="object" rid-ob="figobfaTfanconianemianotablepathogenicv">c.67delG</a> and <a href="/books/NBK1401/table/fa.T.fanconi_anemia_notable_pathogenic_v/?report=objectonly" target="object" rid-ob="figobfaTfanconianemianotablepathogenicv">p.Gln13Ter</a> are associated with a lower risk for congenital anomalies and later progression to bone marrow failure [<a class="bibr" href="#fa.REF.yamashita.1996.4424" rid="fa.REF.yamashita.1996.4424">Yamashita et al 1996</a>, <a class="bibr" href="#fa.REF.gillio.1997.105" rid="fa.REF.gillio.1997.105">Gillio et al 1997</a>].</div></li><li class="half_rhythm"><div><a href="/books/NBK1401/table/fa.T.fanconi_anemia_notable_pathogenic_v/?report=objectonly" target="object" rid-ob="figobfaTfanconianemianotablepathogenicv">c.165+1G>T</a> founder variant in a Saudi population has been associated with a milder phenotype [<a class="bibr" href="#fa.REF.hartmann.2010.480" rid="fa.REF.hartmann.2010.480">Hartmann et al 2010</a>].</div></li></ul></div><div id="fa.Prevalence"><h3>Prevalence</h3><p>Fanconi anemia (FA) is the most common genetic cause of aplastic anemia and one of the most common genetic causes of hematologic malignancy.</p><p>The ratio of males to females is 1.2:1 (p<0.001 vs expected 1.00).</p><p><a class="bibr" href="#fa.REF.rosenberg.2011.1877" rid="fa.REF.rosenberg.2011.1877">Rosenberg et al [2011]</a> showed higher carrier rates for FA than previously reported. Carrier frequency was 1:181 in North Americans and 1:93 in Israel. Specific populations have founder variants with increased carrier frequencies (<1:100), including Ashkenazi Jews (<i>FANCC</i>, <i>BRCA2</i>), northern Europeans (<i>FANCC</i>), Afrikaners (<i>FANCA</i>), sub-Saharan Blacks (<i>FANCG</i>), Spanish Gypsies (<i>FANCA</i>), and others.</p></div></div><div id="fa.Genetically_Related_Allelic_Disorders"><h2 id="_fa_Genetically_Related_Allelic_Disorders_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with germline pathogenic variants in <i>FAAP100</i>, <i>FANCB</i>, <i>FANCC</i>, <i>FANCD2</i>, <i>FANCE</i>, <i>FANCF</i>, <i>FANCG</i>, <i>FANCI</i>, <i>FANCL</i>, <i>REV7/MAD2L2</i>, <i>RFWD3</i>, <i>SLX4</i>, or <i>UBE2T</i>.</p><p>Other phenotypes associated with germline pathogenic variants in <i>BRCA1</i>, <i>BRCA2</i>, <i>BRIP1</i>, <i>ERCC4</i>, <i>FANCA</i>, <i>FANCM</i>, <i>PALB2</i>, <i>RAD51</i>, <i>RAD51C</i>, and <i>XRCC2</i> are summarized in <a href="/books/NBK1401/table/fa.T.allelic_disorders/?report=objectonly" target="object" rid-ob="figobfaTallelicdisorders">Table 3</a>.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figfaTallelicdisorders"><a href="/books/NBK1401/table/fa.T.allelic_disorders/?report=objectonly" target="object" title="Table 3. " class="img_link icnblk_img" rid-ob="figobfaTallelicdisorders"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="fa.T.allelic_disorders"><a href="/books/NBK1401/table/fa.T.allelic_disorders/?report=objectonly" target="object" rid-ob="figobfaTallelicdisorders">Table 3. </a></h4><p class="float-caption no_bottom_margin">Allelic Disorders </p></div></div><p><b>Sporadic tumors</b> (including multiple squamous cell carcinomas, other carcinomas, melanoma, malignant peripheral nerve sheath tumor, glioblastoma, diffuse large B-cell lymphoma, Ewing sarcoma, AML [<a class="bibr" href="#fa.REF.nalepa.2018.168" rid="fa.REF.nalepa.2018.168">Nalepa & Clapp 2018</a>], and pancreatic neuroendocrine tumor [<a class="bibr" href="#fa.REF.zheng.2021.415" rid="fa.REF.zheng.2021.415">Zheng et al 2021</a>]) occurring as single tumors in the absence of any other findings of Fanconi anemia frequently contain somatic variants in FA-related genes that are not present in the germline. In some instances the mutated FA gene appears to function as a tumor suppressor, in others as an oncogene (particularly <i>FANCD2</i>). In these circumstances predisposition to these tumors is not heritable. Somatic FA variants and sporadic tumors are reviewed in two recent publications [<a class="bibr" href="#fa.REF.nalepa.2018.168" rid="fa.REF.nalepa.2018.168">Nalepa & Clapp 2018</a>, <a class="bibr" href="#fa.REF.niraj.2019.457" rid="fa.REF.niraj.2019.457">Niraj et al 2019</a>].</p></div><div id="fa.Differential_Diagnosis"><h2 id="_fa_Differential_Diagnosis_">Differential Diagnosis</h2><p>Cells derived from individuals with other chromosome breakage syndromes may also exhibit high rates of spontaneous chromosome breakage; however, only cells derived from individuals with Fanconi anemia (FA) exhibit increased chromosome breakage in response to diepoxybutane (DEB). See <a href="/books/NBK1401/table/fa.T.genes_and_disorders_of_interest_in/?report=objectonly" target="object" rid-ob="figobfaTgenesanddisordersofinterestin">Table 4</a> for selected examples of chromosome breakage syndromes and for other disorders to consider in the differential diagnosis of FA.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figfaTgenesanddisordersofinterestin"><a href="/books/NBK1401/table/fa.T.genes_and_disorders_of_interest_in/?report=objectonly" target="object" title="Table 4. " class="img_link icnblk_img" rid-ob="figobfaTgenesanddisordersofinterestin"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="fa.T.genes_and_disorders_of_interest_in"><a href="/books/NBK1401/table/fa.T.genes_and_disorders_of_interest_in/?report=objectonly" target="object" rid-ob="figobfaTgenesanddisordersofinterestin">Table 4. </a></h4><p class="float-caption no_bottom_margin">Genes and Disorders of Interest in the Differential Diagnosis of Fanconi Anemia </p></div></div><p><b>VACTERL association</b> (<i>v</i>ertebral defects, <i>a</i>nal atresia, <i>t</i>racheoesophageal fistula with <i>e</i>sophageal atresia, and <i>r</i>adial or renal dysplasia; OMIM <a href="https://omim.org/entry/192350" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">192350</a>) can also be considered in the differential diagnosis. VACTERL association can be distinguished from FA by testing for chromosome breakage with DEB and MMC. The molecular cause of VACTERL association is unknown.</p></div><div id="fa.Management"><h2 id="_fa_Management_">Management</h2><div id="fa.Evaluations_Following_Initial_Diagnos"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and management requirements in an individual diagnosed with Fanconi anemia (FA), the evaluations summarized in <a href="/books/NBK1401/table/fa.T.recommended_evaluations_following_i/?report=objectonly" target="object" rid-ob="figobfaTrecommendedevaluationsfollowingi">Table 5</a> (if not performed as part of the evaluation that led to the diagnosis) are recommended (see also 2020 consensus guidelines [<a href="https://www.fanconi.org/explore/clinical-care-guidelines" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">full text</a>]).</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figfaTrecommendedevaluationsfollowingi"><a href="/books/NBK1401/table/fa.T.recommended_evaluations_following_i/?report=objectonly" target="object" title="Table 5. " class="img_link icnblk_img" rid-ob="figobfaTrecommendedevaluationsfollowingi"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="fa.T.recommended_evaluations_following_i"><a href="/books/NBK1401/table/fa.T.recommended_evaluations_following_i/?report=objectonly" target="object" rid-ob="figobfaTrecommendedevaluationsfollowingi">Table 5. </a></h4><p class="float-caption no_bottom_margin">Recommended Evaluations Following Initial Diagnosis in Individuals with Fanconi Anemia </p></div></div></div><div id="fa.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Recommendations for treatment were agreed upon at a 2014 consensus conference and updated in 2020 (<a href="https://fanconi.org/explore/clinical-care-guidelines" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">full text</a>).</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figfaTtreatmentofmanifestationsinindi"><a href="/books/NBK1401/table/fa.T.treatment_of_manifestations_in_indi/?report=objectonly" target="object" title="Table 6. " class="img_link icnblk_img" rid-ob="figobfaTtreatmentofmanifestationsinindi"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="fa.T.treatment_of_manifestations_in_indi"><a href="/books/NBK1401/table/fa.T.treatment_of_manifestations_in_indi/?report=objectonly" target="object" rid-ob="figobfaTtreatmentofmanifestationsinindi">Table 6. </a></h4><p class="float-caption no_bottom_margin">Treatment of Manifestations in Individuals with Fanconi Anemia </p></div></div><p><b>Androgens</b> improve (at least transiently) the red cell and platelet counts in approximately 50% of individuals. Androgen therapy can be considered when the hemoglobin drops below 8 g/dL or the platelet count falls below 30,000/mm<sup>3</sup> ("severe" – see <a href="/books/NBK1401/table/fa.T.severity_of_bone_marrow_failure_in/?report=objectonly" target="object" rid-ob="figobfaTseverityofbonemarrowfailurein">Table 2</a>). Oxymetholone therapy suppresses osteopontin transcription and induces hematopoietic stem cell cycling in Fanconi mice suggesting downregulation of osteopontin as an important potential mechanism for the drug's action [<a class="bibr" href="#fa.REF.zhang.2015.90" rid="fa.REF.zhang.2015.90">Zhang et al 2015</a>]. Although only 10%-20% of individuals receiving continuous low-dose androgen therapy are long-term responders, this option can be particularly useful for individuals who do not have access to or are not ready for hematopoietic stem cell transplant (HSCT), or to individuals for whom of a suitable donor is not available.</p><ul><li class="half_rhythm"><div>Oxymetholone, given orally at a starting dose of 2 mg/kg/day, may be increased up to 5 mg/kg/day.</div></li><li class="half_rhythm"><div>Doses may be slowly tapered to the minimal effective dose with careful monitoring of the blood counts.</div></li><li class="half_rhythm"><div>Other synthetic androgens used in FA include stanozolol in Asia, and oxandrolone and danazol in North America.</div></li></ul><p>Side effects of androgen administration include virilization and liver toxicity (e.g., elevated liver enzymes, cholestasis, peliosis hepatis [vascular lesion with multiple blood-filled cysts], and hepatic tumors). Individuals taking androgens should be monitored for liver tumors and undergo regular liver function tests (LFTs) for abnormalities. Blood tests for LFTs should be performed every three to six months; liver ultrasound should be performed every six to twelve months. If no response is seen after three to four months, androgens should be discontinued [<a class="bibr" href="#fa.REF.scheckenbach.2012.128" rid="fa.REF.scheckenbach.2012.128">Scheckenbach et al 2012</a>, <a class="bibr" href="#fa.REF.rose.2014.11" rid="fa.REF.rose.2014.11">Rose et al 2014</a>, <a class="bibr" href="#fa.REF.paustian.2016.5" rid="fa.REF.paustian.2016.5">Paustian et al 2016</a>].</p><p><b>Granulocyte colony-stimulating factor</b>
|
|
<b>(G-CSF)</b> improves the neutrophil count in some individuals. G-CSF dose should be titrated to the lowest possible dose and frequency to keep ANC above 1,000/mm<sup>3</sup>. Note: (1) A bone marrow aspirate and biopsy should be performed prior to the initiation of G-CSF and monitored every six months throughout treatment, given the theoretic risk of stimulating the growth of a leukemic clone. (2) G-CSF should be administered in consultation with an FA expert.</p><p><b>HSCT</b> is the only curative therapy for the hematologic manifestations, including aplastic anemia, myelodysplastic syndrome, and acute leukemia. Ideally, HSCT is performed prior to onset of MDS/AML and before multiple transfusions [<a class="bibr" href="#fa.REF.mehta.2010.180" rid="fa.REF.mehta.2010.180">Mehta et al 2010</a>, <a class="bibr" href="#fa.REF.ebens.2017.81" rid="fa.REF.ebens.2017.81">Ebens et al 2017</a>]. Individuals with FA are sensitive to chemotherapy and radiation, need special transplant regimens, and should be cared for and transplanted at centers with the most experience in HSCT in FA.</p><p>A multi-institutional study reported a one-year probability of overall survival of 80% in 45 individuals with FA transplanted for marrow failure and/or MDS, using alternative donors (including mismatched related and unrelated donors) and chemotherapy-only preparative regimen. Survival for individuals younger than age ten years transplanted for marrow failure was even better, at 91.3% (±5.9%) [<a class="bibr" href="#fa.REF.mehta.2017.2308" rid="fa.REF.mehta.2017.2308">Mehta et al 2017</a>].</p><p>Fludarabine reduced the incidence of graft failure and allowed for removal of radiation from the preparative regimens in a matched sib donor setting [<a class="bibr" href="#fa.REF.macmillan.2015.3798" rid="fa.REF.macmillan.2015.3798">MacMillan et al 2015</a>]. Transplant outcomes for recipients of alternative stem cell donors have achieved those of matched sib donors [<a class="bibr" href="#fa.REF.mehta.2017.2308" rid="fa.REF.mehta.2017.2308">Mehta et al 2017</a>, <a class="bibr" href="#fa.REF.ebens.2018.765" rid="fa.REF.ebens.2018.765">Ebens et al 2018</a>]. Newer approaches to graft manipulation, either in vivo or ex vivo, permit use of haploidentical donors without prohibitive rates of graft-vs-host disease (GVHD) [<a class="bibr" href="#fa.REF.bonfim.2017.310" rid="fa.REF.bonfim.2017.310">Bonfim et al 2017</a>, <a class="bibr" href="#fa.REF.strocchio.2021.1333" rid="fa.REF.strocchio.2021.1333">Strocchio et al 2021</a>, <a class="bibr" href="#fa.REF.zubicaray.2021.571" rid="fa.REF.zubicaray.2021.571">Zubicaray et al 2021</a>].</p><p><b>MDS/AML</b> treatment remains challenging. Options include chemotherapy, HSCT with or without prior induction chemotherapy, and investigational trials. Chemotherapy should be undertaken in coordination with centers experienced with FA, as it can cause severe, prolonged, or irreversible myelosuppression. Plans for HSCT should be in place prior to starting chemotherapy. Published reports of chemotherapy regimens for AML in individuals with FA are sparse and limited by the unclear benefit to the overall outcome due to the lack of longitudinal follow up [<a class="bibr" href="#fa.REF.mehta.2007.668" rid="fa.REF.mehta.2007.668">Mehta et al 2007</a>, <a class="bibr" href="#fa.REF.talbot.2014.e199" rid="fa.REF.talbot.2014.e199">Talbot et al 2014</a>, <a class="bibr" href="#fa.REF.mitchell.2014.384" rid="fa.REF.mitchell.2014.384">Mitchell et al 2014</a>]. Recently published EBMT (European Society for Blood and Marrow Transplantation) experience suggests a survival benefit to achieving a complete remission prior to HSCT [<a class="bibr" href="#fa.REF.giardino.2020.809" rid="fa.REF.giardino.2020.809">Giardino et al 2020</a>].</p><p><b>Solid tumors.</b> Prompt, aggressive workup for any symptoms suggestive of a malignancy is indicated. Early detection and surgical removal remain the mainstay of therapy. Treatment is challenging due to the increased toxicity associated with chemotherapy and radiation in individuals with FA. Data is limited on use of chemotherapy at standard doses or reduced doses and schedules in individuals with FA, and there are reports of severe or fatal toxicities and poor treatment outcomes [<a class="bibr" href="#fa.REF.masserot.2008.3315" rid="fa.REF.masserot.2008.3315">Masserot et al 2008</a>, <a class="bibr" href="#fa.REF.tan.2011.e591" rid="fa.REF.tan.2011.e591">Tan et al 2011</a>, <a class="bibr" href="#fa.REF.spanier.2012.510" rid="fa.REF.spanier.2012.510">Spanier et al 2012</a>, <a class="bibr" href="#fa.REF.kutler.2016.870" rid="fa.REF.kutler.2016.870">Kutler et al 2016</a>]. Individuals diagnosed with a genital tract cancer should be referred to a gynecologic oncologist immediately, and care should be coordinated with FA experts.</p></div><div id="fa.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p>Human papilloma virus (HPV) vaccination should be initiated at age nine years in order to reduce the risk of gynecologic cancer in females, and possibly reduce the risk of oral cancer in all individuals.</p></div><div id="fa.Prevention_of_Secondary_Complications"><h3>Prevention of Secondary Complications</h3><p>Individuals with FA treated with HSCT who developed GVHD had a 28% incidence of head and neck cancers in the ten years following treatment (vs 0% in those without GVHD); this finding points to the importance of minimizing the risk of GVHD [<a class="bibr" href="#fa.REF.guardiola.2004.73" rid="fa.REF.guardiola.2004.73">Guardiola et al 2004</a>]. Increased risk for GVHD observed in earlier studies was reduced significantly by T-cell depletion of the donor graft [<a class="bibr" href="#fa.REF.chaudhury.2008.644" rid="fa.REF.chaudhury.2008.644">Chaudhury et al 2008</a>, <a class="bibr" href="#fa.REF.macmillan.2015.3798" rid="fa.REF.macmillan.2015.3798">MacMillan et al 2015</a>].</p><p>Individuals successfully treated with HSCT are at increased risk for solid tumors, in addition to the baseline increased risk [<a class="bibr" href="#fa.REF.rosenberg.2005.67" rid="fa.REF.rosenberg.2005.67">Rosenberg et al 2005</a>]. Due to the known contribution of radiation to the long-term complication of secondary solid tumors, most recent efforts have focused on using a conditioning regimen without radiation even in an unrelated donor setting. German, Brazilian, Turkish, and US groups now report excellent outcomes with alternative donors with a "chemotherapy-only" preparative regimen in single- and multi-center studies. The study from Germany showed 88% survival and normal hematopoiesis at a median follow up of 30 months. A prospective multi-institutional US study also showed similar excellent outcomes. One-year probabilities of overall and disease-free survival for the entire cohort, including individuals with myeloid malignancy and those receiving mismatched related/haploidentical grafts, were 80% and 77.7% respectively at a median follow-up of 41 months. All young children (age <10 years) undergoing HSCT for marrow failure using low-dose busulfan-containing regimen survived [<a class="bibr" href="#fa.REF.bonfim.2015.s94" rid="fa.REF.bonfim.2015.s94">Bonfim et al 2015</a>, <a class="bibr" href="#fa.REF.chao.2015.1311" rid="fa.REF.chao.2015.1311">Chao et al 2015</a>, <a class="bibr" href="#fa.REF.mehta.2017.2308" rid="fa.REF.mehta.2017.2308">Mehta et al 2017</a>].</p></div><div id="fa.Surveillance"><h3>Surveillance</h3><p>See 2020 consensus guidelines (<a href="https://www.fanconi.org/explore/clinical-care-guidelines" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">full text</a>).</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figfaTrecommendedsurveillanceforindivi"><a href="/books/NBK1401/table/fa.T.recommended_surveillance_for_indivi/?report=objectonly" target="object" title="Table 7. " class="img_link icnblk_img" rid-ob="figobfaTrecommendedsurveillanceforindivi"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="fa.T.recommended_surveillance_for_indivi"><a href="/books/NBK1401/table/fa.T.recommended_surveillance_for_indivi/?report=objectonly" target="object" rid-ob="figobfaTrecommendedsurveillanceforindivi">Table 7. </a></h4><p class="float-caption no_bottom_margin">Recommended Surveillance for Individuals with Fanconi Anemia </p></div></div><p><b>Additional cancer surveillance for individuals with Fanconi anemia.</b> Some of the genes associated with FA are known breast cancer susceptibility genes: <i>BRCA1</i>, <i>BRCA2</i>, <i>BRIP1</i>, <i>PALB2</i>, and <i>RAD51C</i>. Individuals who have FA due to pathogenic variants in one of these genes should follow the National Comprehensive Cancer Network (NCCN) screening guidelines that have been developed for individuals with a heterozygous pathogenic variant in one of these genes. This should be done under the care of a genetic health care professional. To date, the risk of breast cancer has not been established in individuals with FA due to biallelic pathogenic variants in these genes, and no additional recommendations have been determined for breast cancer screening.</p></div><div id="fa.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p><b>Blood transfusions.</b> Blood products should be cytomegalovirus (CMV)-safe and irradiated. To reduce the chances of sensitization, family members must not act as blood donors. Once an individual requires transfusions, the individual should be referred for transplantation.</p><p><b>Toxic agents</b> to avoid include smoking, second-hand smoke, and alcohol, which have been implicated in tumorigenesis.</p><p><b>Excessive sun exposure.</b> Sunscreen and sun protective clothing should be used to limit UV exposure.</p><p><b>Unsafe sex practices</b> increase the risk for HPV-associated malignancy.</p><p><b>Radiographic studies</b> for the purpose of surveillance should be minimized in the absence of clinical indications. However, baseline skeletal surveys may be considered, in order to document bony anomalies that may lead to problems with age, such as anomalies of the wrist, hip, and vertebrae.</p></div><div id="fa.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate all sibs of an affected individual in order to identify as early as possible those who would benefit from appropriate monitoring for FA-related physical abnormalities, bone marrow failure, and related cancers. Evaluations include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the pathogenic variant(s) in the family are known;</div></li><li class="half_rhythm"><div>Cytogenetic testing of lymphocytes with diepoxybutane (DEB) and mitomycin C (MMC) for detection of increased chromosome breakage and radial forms.</div></li></ul><p><b>Breast cancer susceptibility.</b> Some of the genes associated with FA are known breast cancer susceptibility genes (see <a href="#fa.Genetically_Related_Allelic_Disorders">Genetically Related Disorders</a>). Family members found to have a pathogenic variant in a known breast cancer susceptibility gene should undergo cancer screening as recommended in the <a href="https://www.nccn.org/guidelines/category_2" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic</a> (no-fee registration and login required) and under the care of a genetic health care professional.</p><p>See <a href="#fa.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for genetic counseling purposes.</p></div><div id="fa.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Pregnancy is possible in females with FA, whether or not they have undergone HSCT [<a class="bibr" href="#fa.REF.nabhan.2010.1783" rid="fa.REF.nabhan.2010.1783">Nabhan et al 2010</a>, <a class="bibr" href="#fa.REF.tsui.2019.199" rid="fa.REF.tsui.2019.199">Tsui & Crismani 2019</a>].</p><p>Pregnancy needs to be managed by a high-risk maternal fetal obstetrician along with a hematologist.</p></div><div id="fa.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p><b>Gene therapy.</b> Several early phase clinical trials of gene therapy targeting <i>FANCA</i> are under way using lentiviral vectors at sites across the world, including the University of Washington/Fred Hutchinson Cancer Research Center and Stanford University in the United States, as well as Hospital Universitari Vall d’Hebron Research Institute in Spain and Shenzhen Geno-Immune Medical Institute in China.</p><p>Separately, the United States National Heart, Lung, and Blood Institute completed a Phase I trial of retroviral vector transduction of autologous CD34+ stem cells in individuals with <i>FANCC</i>-FA (results pending).</p><p>While some trials aim to correct CD34+ stem cells obtained from bone marrow harvest, others are exploring peripheral blood mobilization with combination of G-CSF and plerixafor, shown advantageous in pre-clinical models [<a class="bibr" href="#fa.REF.r_o.2017.1535" rid="fa.REF.r_o.2017.1535">Río et al 2017</a>].</p><p><b>HSCT.</b> A multi-center study (Cincinnati Children’s Hospital Medical Center, Memorial Sloan Kettering Cancer Center, and Fred Hutchinson Cancer Research Center) is investigating risk-adjusted busulfan dosing in a chemotherapy-only conditioning regimen for HSCT in Fanconi anemia (including individuals with MDS and leukemia in addition to those with bone marrow failure as HSCT indication).</p><p><i>Ex vivo</i> T cell receptor alpha/beta depletion of the stem cell product in HSCT is additionally under investigation at the University of Minnesota to reduce the risk of GVHD and allow avoidance of post-HSCT immune suppression.</p><p>A Phase I/II trial will incorporate an anti-cKIT antibody into HSCT conditioning to aid in myeloablation and reduce chemotherapy/radiation toxicity. This will be given in combination with T-cell receptor alpha/beta depletion of the stem cell product to individuals older than age two years with bone marrow failure as the HSCT indication (Jasper Therapeutics sponsored at Stanford University in California).</p><p><b>Hematopoiesis support.</b> Phase I/II studies of the antioxidant quercetin, anti-hyperglycemic metformin and thrombopoietin mimetic eltrombopag are currently under way in the United States for marrow failure in children and adults with FA.</p><p><b>Squamous cell carcinoma (SCC).</b> A Phase II study of the antioxidant quercetin for prevention of SCC in individuals with FA is also currently under way at Cincinnati Children’s Hospital Medical Center.</p><p>Search <a href="https://clinicaltrials.gov" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">ClinicalTrials.gov</a> in the US and <a href="https://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="fa.Genetic_Counseling"><h2 id="_fa_Genetic_Counseling_">Genetic Counseling</h2><p>
|
|
<i>Genetic counseling is the process of providing individuals and families with
|
|
information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them
|
|
make informed medical and personal decisions. The following section deals with genetic
|
|
risk assessment and the use of family history and genetic testing to clarify genetic
|
|
status for family members; it is not meant to address all personal, cultural, or
|
|
ethical issues that may arise or to substitute for consultation with a genetics
|
|
professional</i>. —ED.</p><div id="fa.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Fanconi anemia (FA) is inherited in an autosomal recessive manner, an autosomal dominant manner (<i>RAD51</i>-related FA), or an X-linked manner (<i>FANCB</i>-related FA).</p></div><div id="fa.Autosomal_Recessive_Inheritance__Risk"><h3>Autosomal Recessive Inheritance – Risk to Family Members</h3><p>
|
|
<b>Parents of a proband</b>
|
|
</p><ul><li class="half_rhythm"><div>The parents of a child with autosomal recessive FA are obligate heterozygotes (i.e., presumed to be carriers of one FA-related pathogenic variant based on family history).</div></li><li class="half_rhythm"><div>Molecular genetic testing is recommended for the parents of a proband to confirm that both parents are heterozygous for an FA-related pathogenic variant and to allow reliable recurrence risk assessment.</div></li><li class="half_rhythm"><div>If a pathogenic variant is detected in only one parent of a child with autosomal recessive FA, the following possibilities should be considered:</div><ul><li class="half_rhythm"><div><b>A <i>de novo</i> pathogenic variant.</b> One of the pathogenic variants identified in the proband occurred as a <i>de novo</i> event in the proband or as a postzygotic <i>de novo</i> event in a mosaic parent [<a class="bibr" href="#fa.REF.j_nsson.2017.519" rid="fa.REF.j_nsson.2017.519">Jónsson et al 2017</a>].</div></li><li class="half_rhythm"><div><b>Uniparental isodisomy</b> for the parental chromosome with the pathogenic variant resulting in homozygosity for the pathogenic variant in the proband.</div></li></ul></li><li class="half_rhythm"><div>Heterozygotes are not at risk for autosomal recessive FA. However, heterozygous mutation of a subset of FA-related genes (e.g., <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, <i>BRIP1,</i> and <i>RAD51C</i>) is associated with an increased risk for breast and other cancers (see <a href="#fa.Genetically_Related_Allelic_Disorders">Genetically Related Disorders</a> and <a href="/books/n/gene/brca1/?report=reader"><i>BRCA1</i>- and <i>BRCA2</i>-Associated Hereditary Breast and Ovarian Cancer</a>).</div></li></ul><p>
|
|
<b>Sibs of a proband</b>
|
|
</p><ul><li class="half_rhythm"><div>If both parents are known to be heterozygous for an autosomal recessive FA-related pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being a heterozygote, and a 25% chance of inheriting neither of the familial FA-related pathogenic variants.</div></li><li class="half_rhythm"><div>Heterozygotes are not at risk for FA. However, heterozygous mutation of a subset of FA-related genes (e.g., <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i>, <i>BRIP1,</i> and <i>RAD51C</i>) is associated with an increased risk for breast and other cancers [<a class="bibr" href="#fa.REF.seal.2006.1239" rid="fa.REF.seal.2006.1239">Seal et al 2006</a>, <a class="bibr" href="#fa.REF.berwick.2007.9591" rid="fa.REF.berwick.2007.9591">Berwick et al 2007</a>, <a class="bibr" href="#fa.REF.reid.2007.162" rid="fa.REF.reid.2007.162">Reid et al 2007</a>] (see <a href="#fa.Genetically_Related_Allelic_Disorders">Genetically Related Disorders</a> and <a href="/books/n/gene/brca1/?report=reader"><i>BRCA1</i>- and <i>BRCA2</i>-Associated Hereditary Breast and Ovarian Cancer</a>).</div></li></ul><p><b>Offspring of a proband.</b> The offspring of an individual with autosomal recessive FA are obligate heterozygotes for a pathogenic variant in an FA-related gene.</p><p><b>Other family members.</b> Each sib of the proband's parents is at a 50% risk of being heterozygous for a pathogenic variant in an FA-related gene.</p><p><b>Heterozygote detection.</b> Heterozygote testing for at-risk relatives requires prior identification of the FA-related pathogenic variants in the family.</p><p>Individuals who are heterozygous for an autosomal recessive FA-related pathogenic variant cannot be detected by the DEB/MMC test.</p></div><div id="fa.Autosomal_Dominant_Inheritance__Risk"><h3>Autosomal Dominant Inheritance – Risk to Family Members</h3><p>
|
|
<b>Parents of a proband</b>
|
|
</p><ul><li class="half_rhythm"><div>All probands with <i>RAD51</i>-related FA reported to date have the disorder as a result of a <i>de novo</i>
|
|
<i>RAD51</i> pathogenic variant.</div></li><li class="half_rhythm"><div>Molecular genetic testing is recommended for the parents of the proband evaluate their genetic status and inform recurrence risk assessment.</div></li><li class="half_rhythm"><div>If the pathogenic variant identified in the proband is not identified in either parent, the following possibilities should be considered:</div><ul><li class="half_rhythm"><div>The proband has a <i>de novo</i> pathogenic variant. Note: A pathogenic variant is reported as "<i>de novo</i>" if: (1) the pathogenic variant found in the proband is not detected in parental DNA; and (2) parental identity testing has confirmed biological maternity and paternity. If parental identity testing is not performed, the variant is reported as "assumed <i>de novo</i>" [<a class="bibr" href="#fa.REF.richards.2015.405" rid="fa.REF.richards.2015.405">Richards et al 2015</a>].</div></li><li class="half_rhythm"><div>The proband inherited a pathogenic variant from a parent with germline (or somatic and germline) mosaicism. Note: Testing of parental leukocyte DNA may not detect all instances of somatic mosaicism and will not detect a pathogenic variant that is present in the germ cells only.</div></li></ul></li></ul><p><b>Sibs of a proband.</b> The risk to the sibs of the proband depends on the genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent of the proband has the pathogenic variant identified in the proband, the risk to the sibs of inheriting the pathogenic variant is 50%.</div></li><li class="half_rhythm"><div>If the <i>RAD51</i> pathogenic variant identified in the proband cannot be detected in the leukocyte DNA of either parent, the recurrence risk to sibs is estimated to be 1% because of the theoretic possibility of parental germline mosaicism [<a class="bibr" href="#fa.REF.rahbari.2016.126" rid="fa.REF.rahbari.2016.126">Rahbari et al 2016</a>]. (Parental germline mosaicism has not been described to date in <i>RAD51-</i>related FA.)</div></li></ul><p><b>Offspring of a proband.</b> Each child of an individual with <i>RAD51</i>-related FA is presumed to have a 50% chance of inheriting the pathogenic variant; however, only one individual with <i>RAD51</i>-related FA has reached adulthood and no offspring have been reported.</p><p><b>Other family members.</b> Given that all probands with <i>RAD51</i>-related FA reported to date have the disorder as a result of a <i>de novo</i>
|
|
<i>RAD51</i> pathogenic variant, the risk to other family members is presumed to be low.</p></div><div id="fa.XLinked_Inheritance__Risk_to_Family_M"><h3>X-Linked Inheritance – Risk to Family Members</h3><p>
|
|
<b>Parents of a male proband</b>
|
|
</p><ul><li class="half_rhythm"><div>The father of a male with X-linked FA will not have the disorder nor will he be hemizygous for the <i>FANCB</i> pathogenic variant; therefore, he does not require further evaluation/testing.</div></li><li class="half_rhythm"><div>In a family with more than one affected individual, the mother of an affected male is an obligate heterozygote (carrier). Note: If a woman has more than one affected child and no other affected relatives and if the <i>FANCB</i> pathogenic variant cannot be detected in her leukocyte DNA, she most likely has germline mosaicism.</div></li><li class="half_rhythm"><div>If a male is the only affected family member (i.e., a simplex case), the mother may be a heterozygote (carrier), the affected male may have a <i>de novo</i>
|
|
<i>FANCB</i> pathogenic variant (in which case the mother is not a carrier), or the mother may have somatic/germline mosaicism.</div></li><li class="half_rhythm"><div>Molecular genetic testing of the mother is recommended to confirm her genetic status and to allow reliable recurrence risk assessment.</div></li></ul><p><b>Sibs of a male proband.</b> The risk to sibs depends on the genetic status of the mother:</p><ul><li class="half_rhythm"><div>If the mother of the proband has a <i>FANCB</i> pathogenic variant, the chance of the mother transmitting it in each pregnancy is 50%.</div><ul><li class="half_rhythm"><div>Male sibs who inherit the pathogenic variant will be affected;</div></li><li class="half_rhythm"><div>Female sibs who inherit the pathogenic variant will be heterozygotes and will usually not be affected [<a class="bibr" href="#fa.REF.mccauley.2011.2370" rid="fa.REF.mccauley.2011.2370">McCauley et al 2011</a>].</div></li></ul></li><li class="half_rhythm"><div>If the proband represents a simplex case (i.e., a single occurrence in a family) and if the <i>FANCB</i> pathogenic variant cannot be detected in the leukocyte DNA of the mother, the risk to sibs is low but greater than that of the general population because of the possibility of maternal germline mosaicism.</div></li></ul><p>
|
|
<b>Offspring of a male proband</b>
|
|
</p><ul><li class="half_rhythm"><div>Affected males transmit the <i>FANCB</i> pathogenic variant to all of their daughters (who will be heterozygotes and will usually not be affected) and none of their sons.</div></li><li class="half_rhythm"><div>To date, no male with <i>FANCB</i>-related FA has been old enough to have children; they may also be infertile, as are many males with FA. Further, <i>FANCB</i> has been demonstrated essential to regulation of spermatogenesis and affected mice are infertile [<a class="bibr" href="#fa.REF.kato.2015.5234" rid="fa.REF.kato.2015.5234">Kato et al 2015</a>].</div></li></ul><p><b>Other family members.</b> The proband's maternal aunts may be at risk of being heterozygotes (carriers) for the <i>FANCB</i> pathogenic variant and the aunt's offspring, depending on their sex, may be at risk of being heterozygotes or of being affected.</p><p>Note: Molecular genetic testing may be able to identify the family member in whom a <i>de novo</i> pathogenic variant arose – information that could help determine genetic risk status of the extended family.</p><p><b>Heterozygote detection.</b> Carrier testing for at-risk female relatives requires prior identification of the <i>FANCB</i> pathogenic variant in the family.</p><p>Individuals who are heterozygous for a <i>FANCB</i> pathogenic variant cannot be detected by the DEB/MMC test.</p></div><div id="fa.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#fa.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p>
|
|
<b>Family planning</b>
|
|
</p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or are heterozygotes (carriers) or who are at increased risk of being heterozygotes.</div></li></ul><p><b>DNA banking.</b> Because it is likely that testing methodology and our understanding of genes, pathogenic mechanisms, and diseases will improve in the future, consideration should be given to banking DNA from probands in whom a molecular diagnosis has not been confirmed (i.e., the causative pathogenic mechanism unknown). For more information, see <a class="bibr" href="#fa.REF.huang.2022.389" rid="fa.REF.huang.2022.389">Huang et al [2022]</a>.</p></div><div id="fa.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Testing</h3><p><b>Molecular genetic testing.</b> Once the FA-related pathogenic variant(s) have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing (PGT) for FA are possible. PGT has successfully identified at-risk embryos as unaffected with FA and HLA-matched to affected sibs [<a class="bibr" href="#fa.REF.kahraman.2014.340" rid="fa.REF.kahraman.2014.340">Kahraman et al 2014</a>, <a class="bibr" href="#fa.REF.rechitsky.2020.220" rid="fa.REF.rechitsky.2020.220">Rechitsky et al 2020</a>].</p><p><b>Chromosome breakage.</b> Prenatal testing is also possible for pregnancies at increased risk for FA by performing cytogenetic testing in the presence of DEB/MMC to evaluate for increased chromosome breakage in fetal cells obtained by chorionic villus sampling (CVS) or amniocentesis [<a class="bibr" href="#fa.REF.auerbach.2003.158" rid="fa.REF.auerbach.2003.158">Auerbach et al 2003</a>]; however, if the pathogenic variants are known in the family, molecular genetic testing is the method of choice for prenatal diagnosis.</p><p><b>Fetal ultrasound evaluation.</b> Ultrasound examination can be used to evaluate for fetal anomalies consistent with FA. However, ultrasound examination is not a diagnostic test for FA. Many congenital anomalies characteristic of FA may not be detectable by ultrasound examination, and those that can be seen may be associated with diagnoses other than FA [<a class="bibr" href="#fa.REF.gandhi.2019.b16" rid="fa.REF.gandhi.2019.b16">Gandhi et al 2019</a>].</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal and preimplantation genetic testing. While most health care professionals would consider use of prenatal and preimplantation genetic testing to be a personal decision, discussion of these issues may be helpful.</p></div></div><div id="fa.Resources"><h2 id="_fa_Resources_">Resources</h2><p>
|
|
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
|
|
support organizations and/or registries for the benefit of individuals with this disorder
|
|
and their families. GeneReviews is not responsible for the information provided by other
|
|
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/?report=reader">here</a>.</i></p>
|
|
<ul><li class="half_rhythm"><div>
|
|
<b>Fanconi Anemia Cell Repository</b>
|
|
</div><div>Department of Medical and Molecular Genetics</div><div>3181 Southwest Sam Jackson Park Road L103</div><div>Oregon Health & Science University</div><div>Portland OR 97201</div><div><b>Phone:</b> 503-494-6888</div></li><li class="half_rhythm"><div>
|
|
<b>Fanconi Anemia Research Fund, Inc. (FARF)</b>
|
|
</div><div>1801 Williamette Street</div><div>Suite 200</div><div>Eugene OR 97401</div><div><b>Phone:</b> 888-326-2664 (Toll-free Family Support Line); 541-687-4658</div><div><b>Fax:</b> 541-687-0548</div><div><b>Email:</b> info@fanconi.org</div><div>
|
|
<a href="http://www.fanconi.org" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">www.fanconi.org</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>International Fanconi Anemia Registry (IFAR)</b>
|
|
</div><div>The Rockefeller University</div><div>1230 York Avenue</div><div>New York NY 10065</div><div><b>Phone:</b> 212-327-8862</div><div><b>Fax:</b> 212-327-8262</div><div><b>Email:</b> auerbac@rockefeller.edu</div><div>
|
|
<a href="http://lab.rockefeller.edu/smogorzewska/ifar/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">International Fanconi Anemia Registry (IFAR)</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<b>National Cancer Institute Inherited Bone Marrow Failure Syndromes (IBMFS) Cohort Registry</b>
|
|
</div><div><b>Phone:</b> 800-518-8474</div><div><b>Email:</b> NCI.IBMFS@westat.com</div><div>
|
|
<a href="https://www.marrowfailure.cancer.gov/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">marrowfailure.cancer.gov</a>
|
|
</div></li></ul>
|
|
</div><div id="fa.Molecular_Genetics"><h2 id="_fa_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —</i>ED.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figfamolgenTA"><a href="/books/NBK1401/table/fa.molgen.TA/?report=objectonly" target="object" title="Table A." class="img_link icnblk_img" rid-ob="figobfamolgenTA"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="fa.molgen.TA"><a href="/books/NBK1401/table/fa.molgen.TA/?report=objectonly" target="object" rid-ob="figobfamolgenTA">Table A.</a></h4><p class="float-caption no_bottom_margin">Fanconi Anemia: Genes and Databases </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figfamolgenTB"><a href="/books/NBK1401/table/fa.molgen.TB/?report=objectonly" target="object" title="Table B." class="img_link icnblk_img" rid-ob="figobfamolgenTB"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="fa.molgen.TB"><a href="/books/NBK1401/table/fa.molgen.TB/?report=objectonly" target="object" rid-ob="figobfamolgenTB">Table B.</a></h4><p class="float-caption no_bottom_margin">OMIM Entries for Fanconi Anemia (View All in OMIM) </p></div></div><p>See <a href="/books/NBK1401/?report=reader#fa.molgen.TA">Table A</a> for gene and protein names.</p><div id="fa.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>At least 23 genes that are involved in Fanconi anemia (FA) and also account for each of the phenotypic complementation groups have been identified. The proteins encoded by the FA-related genes are considered to work together in a common pathway/network called "the FA pathway" or "the FA-BRCA pathway/network," which regulates cellular resistance to DNA cross-linking agents [<a class="bibr" href="#fa.REF.taniguchi.2006.4223" rid="fa.REF.taniguchi.2006.4223">Taniguchi & D'Andrea 2006</a>, <a class="bibr" href="#fa.REF.dandrea.2010.1909" rid="fa.REF.dandrea.2010.1909">D'Andrea 2010</a>, <a class="bibr" href="#fa.REF.deans.2011.467" rid="fa.REF.deans.2011.467">Deans & West 2011</a>, <a class="bibr" href="#fa.REF.kee.2012.3799" rid="fa.REF.kee.2012.3799">Kee & D'Andrea 2012</a>]. Disruption of this pathway leads to the common cellular and clinical abnormalities observed in FA [<a class="bibr" href="#fa.REF.dandrea.2010.1909" rid="fa.REF.dandrea.2010.1909">D'Andrea 2010</a>, <a class="bibr" href="#fa.REF.nakanishi.2011.500" rid="fa.REF.nakanishi.2011.500">Nakanishi et al 2011</a>, <a class="bibr" href="#fa.REF.williams.2011.4395" rid="fa.REF.williams.2011.4395">Williams et al 2011</a>, <a class="bibr" href="#fa.REF.crossan.2012.326" rid="fa.REF.crossan.2012.326">Crossan & Patel 2012</a>, <a class="bibr" href="#fa.REF.kim.2012.1393" rid="fa.REF.kim.2012.1393">Kim & D'Andrea 2012</a>].</p><p>Eight of the FA proteins (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, and FANCM), along with proteins FAAP24 [<a class="bibr" href="#fa.REF.ciccia.2007.331" rid="fa.REF.ciccia.2007.331">Ciccia et al 2007</a>] and FAAP100 [<a class="bibr" href="#fa.REF.ling.2007.2104" rid="fa.REF.ling.2007.2104">Ling et al 2007</a>] are assembled in a nuclear complex (FA core complex). This complex is a multisubunit ubiquitin ligase complex; monoubiquitination of two FA proteins (FANCD2 and FANCI) depends on the FA core complex [<a class="bibr" href="#fa.REF.garciahiguera.2001.249" rid="fa.REF.garciahiguera.2001.249">Garcia-Higuera et al 2001</a>, <a class="bibr" href="#fa.REF.smogorzewska.2007.289" rid="fa.REF.smogorzewska.2007.289">Smogorzewska et al 2007</a>]. In response to DNA damage or in S phase of the cell cycle, this FA core complex activates the monoubiquitination of the FANCD2 and FANCI proteins. Monoubiquitinated FANCD2 and monoubiquitinated FANCI are translocated to nuclear foci containing the proteins BRCA1, BRCA2, PALB2, and RAD51. FANCI shares sequence similarity with FANCD2; together they form a protein complex (ID complex) [<a class="bibr" href="#fa.REF.smogorzewska.2007.289" rid="fa.REF.smogorzewska.2007.289">Smogorzewska et al 2007</a>]. Monoubiquitination of FANCD2 and FANCI is interdependent [<a class="bibr" href="#fa.REF.smogorzewska.2007.289" rid="fa.REF.smogorzewska.2007.289">Smogorzewska et al 2007</a>]. A nuclease, FAN1, has been shown to bind to monoubiquitinated FANCD2, which directs its enzymatic activity [<a class="bibr" href="#fa.REF.huang.2010.926" rid="fa.REF.huang.2010.926">Huang & D'Andrea 2010</a>]. A cell-free system has been used to recapitulate cross-link repair in vitro [<a class="bibr" href="#fa.REF.knipscheer.2009.1698" rid="fa.REF.knipscheer.2009.1698">Knipscheer et al 2009</a>].</p><p>Furthermore, the FA core complex forms a larger complex with BLM, RPA, and topoisomerase IIIα, called BRAFT (<i>B</i>LM, <i>R</i>P<i>A</i>, <i>F</i>A, and <i>t</i>opoisomerase IIIα) [<a class="bibr" href="#fa.REF.meetei.2003.3417" rid="fa.REF.meetei.2003.3417">Meetei et al 2003</a>] in a further link to <a href="/books/n/gene/bloom/?report=reader">Bloom syndrome</a>. FANCM is found in both separable complexes: the FA core complex as well as the BLM complex [<a class="bibr" href="#fa.REF.deans.2009.943" rid="fa.REF.deans.2009.943">Deans & West 2009</a>].</p><p><i>BRCA2</i> (previously <i>FANCD1</i>) is a tumor suppressor that confers breast cancer susceptibility [<a class="bibr" href="#fa.REF.howlett.2002.606" rid="fa.REF.howlett.2002.606">Howlett et al 2002</a>] and has a distinct clinical phenotype [<a class="bibr" href="#fa.REF.wagner.2004.3226" rid="fa.REF.wagner.2004.3226">Wagner et al 2004</a>, <a class="bibr" href="#fa.REF.alter.2007.1" rid="fa.REF.alter.2007.1">Alter et al 2007</a>, <a class="bibr" href="#fa.REF.myers.2012.462" rid="fa.REF.myers.2012.462">Myers et al 2012</a>]. BRCA2 protein stability and localization is regulated by PALB2 (partner and localizer of BRCA2) [<a class="bibr" href="#fa.REF.xia.2006.719" rid="fa.REF.xia.2006.719">Xia et al 2006</a>] encoded by <i>PALB2</i> (previously <i>FANCN</i>), another breast cancer susceptibility gene [<a class="bibr" href="#fa.REF.reid.2007.162" rid="fa.REF.reid.2007.162">Reid et al 2007</a>]. Another breast cancer susceptibility gene [<a class="bibr" href="#fa.REF.seal.2006.1239" rid="fa.REF.seal.2006.1239">Seal et al 2006</a>], <i>BRIP1</i> (previously <i>BACH1</i> or <i>FANCJ</i>) [<a class="bibr" href="#fa.REF.cantor.2001.149" rid="fa.REF.cantor.2001.149">Cantor et al 2001</a>], is also associated with FA [<a class="bibr" href="#fa.REF.levitus.2005.934" rid="fa.REF.levitus.2005.934">Levitus et al 2005</a>, <a class="bibr" href="#fa.REF.levran.2005.931" rid="fa.REF.levran.2005.931">Levran et al 2005</a>, <a class="bibr" href="#fa.REF.litman.2005.255" rid="fa.REF.litman.2005.255">Litman et al 2005</a>]. <i>BRCA2, PALB2</i>, and <i>BRIP1</i> are not required for FANCD2 protein monoubiquitination or FANCD2 nuclear foci formation, but are still required for cellular resistance to MMC or DEB. BRCA2 has been found to act in multiple subcomplexes of FA proteins, including FANCG and FANCD2 [<a class="bibr" href="#fa.REF.wilson.2010.12" rid="fa.REF.wilson.2010.12">Wilson et al 2010</a>], suggesting that the notion of acting downstream of FANCD2 monoubiquitination may be too simplistic. Phosphorylation of FANCD2 by CHK1 has been shown to be necessary for interaction with BRCA2 [<a class="bibr" href="#fa.REF.zhi.2009.8775" rid="fa.REF.zhi.2009.8775">Zhi et al 2009</a>]. BRIP1 and FANCD2 have also been shown to be functionally linked in foci formation [<a class="bibr" href="#fa.REF.zhang.2010.637" rid="fa.REF.zhang.2010.637">Zhang et al 2010</a>].</p><p>Amelioration of FA pathology has been implicated in reports of downregulation of elements of the non-homologous end-joining pathway [<a class="bibr" href="#fa.REF.adamo.2010.25" rid="fa.REF.adamo.2010.25">Adamo et al 2010</a>]. These data propose that much of FA pathophysiology results from the unfettered work of non-homologous end joining promoting inaccurate repair. On the other hand, FA involvement in homologous recombinatorial repair has been well established in interactions with BRCA1, BRCA2, and RAD51C. FANCD2 has also been shown to interact with PCNA and pol K, suggesting that translesion synthesis, a variant of homologous recombination, may be the most direct function of FA proteins in bypass of the lesion [<a class="bibr" href="#fa.REF.ho.2010.552" rid="fa.REF.ho.2010.552">Ho & Schärer 2010</a>, <a class="bibr" href="#fa.REF.song.2010.31525" rid="fa.REF.song.2010.31525">Song et al 2010</a>].</p><p><b>Mechanism of disease causation.</b> Loss of function</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figfaTfanconianemianotablepathogenicv"><a href="/books/NBK1401/table/fa.T.fanconi_anemia_notable_pathogenic_v/?report=objectonly" target="object" title="Table 8. " class="img_link icnblk_img" rid-ob="figobfaTfanconianemianotablepathogenicv"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="fa.T.fanconi_anemia_notable_pathogenic_v"><a href="/books/NBK1401/table/fa.T.fanconi_anemia_notable_pathogenic_v/?report=objectonly" target="object" rid-ob="figobfaTfanconianemianotablepathogenicv">Table 8. </a></h4><p class="float-caption no_bottom_margin">Fanconi Anemia: Notable Pathogenic Variants by Gene </p></div></div></div></div><div id="fa.Chapter_Notes"><h2 id="_fa_Chapter_Notes_">Chapter Notes</h2><div id="fa.Author_Notes"><h3>Author Notes</h3><p><b>Comprehensive Center for Fanconi Anemia</b><br />Dana Farber Cancer Institute <br />Mayer 676 <br />44 Binney Street <br />Boston, MA 02115 <br />Phone: 617-632-6302</p></div><div id="fa.Author_History"><h3>Author History</h3><p>Blanche P Alter, MD, MPH, FAAP; National Cancer Institute (2011-2016)<br />Alan D'Andrea, MD; Dana Farber Cancer Institute (2002-2007) <br />Christen Ebens, MD, MPH (2021-present)<br />Gary Kupfer, MD; Yale University School of Medicine (2011-2016)<br />Parinda A Mehta, MD (2016-present)<br />Lisa Moreau, MS; Dana Farber Cancer Institute (2002-2007) <br />Akiko Shimamura, MD, PhD; Dana Farber Cancer Institute (2002-2007) <br />Toshiyasu Taniguchi, MD, PhD; Fred Hutchinson Cancer Research Center (2007-2011)<br />Jakub Tolar, MD, PhD; University of Minnesota (2016-2021)</p></div><div id="fa.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>3 June 2021 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>22 September 2016 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>10 February 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>22 June 2007 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>13 September 2004 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>14 February 2002 (me) Review posted live</div></li><li class="half_rhythm"><div>31 May 2001 (as) Original submission</div></li></ul></div></div><div id="fa.References"><h2 id="_fa_References_">References</h2><div id="fa.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.adamo.2010.25">Adamo
|
|
A, Collis
|
|
SJ, Adelman
|
|
CA, Silva
|
|
N, Horejsi
|
|
Z, Ward
|
|
JD, Martinez-Perez
|
|
E, Boulton
|
|
SJ, La Volpe
|
|
A. Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia.
|
|
Mol Cell.
|
|
2010;39:25–35.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/20598602" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20598602</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.alter.2006.446">Alter
|
|
BP. The association between FANCD1/BRCA2 mutations and leukaemia.
|
|
Br J Haematol.
|
|
2006;133:446–8.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/16643458" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16643458</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.alter.2010.179">Alter
|
|
BP, Giri
|
|
N, Savage
|
|
SA, Peters
|
|
JA, Loud
|
|
JT, Leathwood
|
|
L, Carr
|
|
AG, Greene
|
|
MH, Rosenberg
|
|
PS. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study.
|
|
Br J Haematol.
|
|
2010;150:179–88.
|
|
[<a href="/pmc/articles/PMC3125983/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3125983</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20507306" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20507306</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.alter.2007.1">Alter
|
|
BP, Rosenberg
|
|
PS, Brody
|
|
LC. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2.
|
|
J Med Genet.
|
|
2007;44:1–9.
|
|
[<a href="/pmc/articles/PMC2597904/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2597904</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16825431" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16825431</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.andreassen.2004.1958">Andreassen
|
|
PR, D'Andrea
|
|
AD, Taniguchi
|
|
T. ATR couples FANCD2 monoubiquitination to the DNA-damage response.
|
|
Genes Dev.
|
|
2004;18:1958–63.
|
|
[<a href="/pmc/articles/PMC514175/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC514175</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15314022" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15314022</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.auerbach.2003.158">Auerbach
|
|
AD, Greenbaum
|
|
J, Pujara
|
|
K, Batish
|
|
SD, Bitencourt
|
|
MA, Kokemohr
|
|
I, Schneider
|
|
H, Lobitzc
|
|
S, Pasquini
|
|
R, Giampietro
|
|
PF, Hanenberg
|
|
H, Levran
|
|
O, et al.
|
|
Spectrum of sequence variation in the FANCG gene: an International Fanconi Anemia Registry (IFAR) study.
|
|
Hum Mutat.
|
|
2003;21:158–68.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/12552564" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12552564</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.berwick.2007.9591">Berwick
|
|
M, Satagopan
|
|
JM, Ben-Porat
|
|
L, Carlson
|
|
A, Mah
|
|
K, Henry
|
|
R, Diotti
|
|
R, Milton
|
|
K, Pujara
|
|
K, Landers
|
|
T, Dev Batish
|
|
S, Morales
|
|
J, Schindler
|
|
D, Hanenberg
|
|
H, Hromas
|
|
R, Levran
|
|
O, Auerbach
|
|
AD. Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer.
|
|
Cancer Res.
|
|
2007;67:9591–6.
|
|
[<a href="/pmc/articles/PMC3622247/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3622247</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17909071" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17909071</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.bonfim.2017.310">Bonfim
|
|
C, Ribeiro
|
|
L, Nichele
|
|
S, Loth
|
|
G, Bitencourt
|
|
M, Koliski
|
|
A, Kuwahara
|
|
C, Fabro
|
|
AL, Pereira
|
|
NF, Pilonetto
|
|
D, Thakar
|
|
M, Kiem
|
|
HP, Page
|
|
K, Fuchs
|
|
EJ, Eapen
|
|
M, Pasquini
|
|
R. Haploidentical bone marrow transplantation with post-transplant cyclophosphamide for children and adolescents with Fanconi anemia.
|
|
Biol Blood Marrow Transplant.
|
|
2017;23:310–17.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/27832981" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27832981</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.bonfim.2015.s94">Bonfim
|
|
C, Ribeiro
|
|
L, Nichele
|
|
S, Loth
|
|
G, Kuwahara
|
|
C, Koliski
|
|
A, Bitencourt
|
|
M, Scherer
|
|
F, Rodrigues
|
|
L, Pilonetto
|
|
D, Pasquini
|
|
R.
|
|
Excellent outcomes for Fanconi anemia patients undergoing hematopoietic stem cell transplantation (HSCT) without radiation: a single center experience on 103 patients.
|
|
Biol Blood Marrow Transplant.
|
|
2015;21:S94.</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.bottega.2018.417">Bottega
|
|
R, Nicchia
|
|
E, Cappelli
|
|
E, Ravera
|
|
S, De Rocco
|
|
D, Faleschini
|
|
M, Corsolini
|
|
F, Pierri
|
|
F, Calvillo
|
|
M, Russo
|
|
G, Casazza
|
|
G, Ramenghi
|
|
U, Farruggia
|
|
P, Dufour
|
|
C, Savoia
|
|
A.
|
|
Hypomorphic FANCA mutations correlate with mild mitochondrial and clinical phenotype in Fanconi anemia.
|
|
Haematologica.
|
|
2018;103:417–26.
|
|
[<a href="/pmc/articles/PMC5830397/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5830397</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29269525" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29269525</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.cantor.2001.149">Cantor
|
|
SB, Bell
|
|
DW, Ganesan
|
|
S, Kass
|
|
EM, Drapkin
|
|
R, Grossman
|
|
S, Wahrer
|
|
DC, Sgroi
|
|
DC, Lane
|
|
WS, Haber
|
|
DA, Livingston
|
|
DM. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function.
|
|
Cell.
|
|
2001;105:149–60.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/11301010" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11301010</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.castella.2011.3759">Castella
|
|
M, Pujol
|
|
R, Callén
|
|
E, Trujillo
|
|
JP, Casado
|
|
JA, Gille
|
|
H, Lach
|
|
FP, Auerbach
|
|
AD, Schindler
|
|
D, Benítez
|
|
J, Porto
|
|
B, Ferro
|
|
T, Muñoz
|
|
A, Sevilla
|
|
J, Madero
|
|
L, Cela
|
|
E, Beléndez
|
|
C, de Heredia
|
|
CD, Olivé
|
|
T, de Toledo
|
|
JS, Badell
|
|
I, Torrent
|
|
M, Estella
|
|
J, Dasí
|
|
A, Rodríguez-Villa
|
|
A, Gómez
|
|
P, Barbot
|
|
J, Tapia
|
|
M, Molinés
|
|
A, Figuera
|
|
A, Bueren
|
|
JA, Surrallés
|
|
J. Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations.
|
|
Blood.
|
|
2011;117:3759–69.
|
|
[<a href="/pmc/articles/PMC3083295/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3083295</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21273304" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21273304</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.chao.2015.1311">Chao
|
|
MM, Kuehl
|
|
JS, Strauss
|
|
G, Hanenberg
|
|
H, Schindler
|
|
D, Neitzel
|
|
H, Niemeyer
|
|
C, Baumann
|
|
I, von Bernuth
|
|
H, Rascon
|
|
J, Nagy
|
|
M, Zimmermann
|
|
M, Kratz
|
|
CP, Ebell
|
|
W. Outcomes of mismatched and unrelated donor hematopoietic stem cell transplantation in Fanconi anemia conditioned with chemotherapy only.
|
|
Ann Hematol.
|
|
2015;94:1311–8.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/25862235" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25862235</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.chaudhury.2008.644">Chaudhury
|
|
S, Auerbach
|
|
AD, Kernan
|
|
NA, Small
|
|
TN, Prockop
|
|
SE, Scaradavou
|
|
A, Heller
|
|
G, Wolden
|
|
S, O'Reilly
|
|
RJ, Boulad
|
|
F. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia.
|
|
Br J Haematol.
|
|
2008;140:644–55.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/18302713" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18302713</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.ciccia.2007.331">Ciccia
|
|
A, Ling
|
|
C, Coulthard
|
|
R, Yan
|
|
Z, Xue
|
|
Y, Meetei
|
|
AR. Laghmani el H, Joenje H, McDonald N, de Winter JP, Wang W, West SC. Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM.
|
|
Mol Cell.
|
|
2007;25:331–43.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/17289582" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17289582</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.crossan.2012.326">Crossan
|
|
GP, Patel
|
|
KJ. The Fanconi anaemia pathway orchestrates incisions at sites of crosslinked DNA.
|
|
J Pathol.
|
|
2012;226:326–37.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/21956823" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21956823</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.dandrea.2010.1909">D'Andrea
|
|
AD. Susceptibility pathways in Fanconi's anemia and breast cancer.
|
|
N Engl J Med.
|
|
2010;362:1909–19.
|
|
[<a href="/pmc/articles/PMC3069698/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3069698</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20484397" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20484397</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.deans.2009.943">Deans
|
|
AJ, West
|
|
SC. FANCM connects the genome instability disorders Bloom's Syndrome and Fanconi Anemia.
|
|
Mol Cell.
|
|
2009;36:943–53.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/20064461" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20064461</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.deans.2011.467">Deans
|
|
AJ, West
|
|
SC. DNA interstrand crosslink repair and cancer.
|
|
Nat Rev Cancer.
|
|
2011;11:467–80.
|
|
[<a href="/pmc/articles/PMC3560328/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3560328</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21701511" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21701511</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.del_valle.2020.829">Del Valle
|
|
J, Rofes
|
|
P, Moreno-Cabrera
|
|
JM, Lopez-Doriga
|
|
A, Belhadj
|
|
S, Vargas-Parra
|
|
G, Teulé
|
|
À, Cuesta
|
|
R, Muñoz
|
|
X, Campos
|
|
O, Salinas
|
|
M, de Cid
|
|
R, Brunet
|
|
J, González
|
|
S, Capellá
|
|
G, Pineda
|
|
M, Feliubadaló
|
|
L, Lázaro
|
|
C. Exploring the role of mutations in Fanconi anemia genes in hereditary cancer patients.
|
|
Cancers (Basel). 2020;12:829.
|
|
[<a href="/pmc/articles/PMC7226125/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7226125</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32235514" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32235514</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.demuth.2000.861">Demuth
|
|
I, Wlodarski
|
|
M, Tipping
|
|
AJ, Morgan
|
|
NV, de Winter
|
|
JP, Thiel
|
|
M, Gräsl
|
|
S, Schindler
|
|
D, D'Andrea
|
|
AD, Altay
|
|
C, Kayserili
|
|
H, Zatterale
|
|
A, Kunze
|
|
J, Ebell
|
|
W, Mathew
|
|
CG, Joenje
|
|
H, Sperling
|
|
K, Digweed
|
|
M. Spectrum of mutations in the Fanconi anaemia group G gene, FANCG/XRCC9.
|
|
Eur J Hum Genet.
|
|
2000;8:861–8.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/11093276" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11093276</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.ebens.2018.765">Ebens
|
|
CL, DeFor
|
|
TE, Tryon
|
|
R, Wagner
|
|
JE, MacMillan
|
|
ML. Comparable outcomes after HLA-matched sibling and alternative donor hematopoietic cell transplantation for children with Fanconi anemia and severe aplastic anemia.
|
|
Biol Blood Marrow Transplant.
|
|
2018;24:765–71.
|
|
[<a href="/pmc/articles/PMC6915968/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6915968</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29203412" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29203412</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.ebens.2017.81">Ebens
|
|
CL, MacMillan
|
|
ML, Wagner
|
|
JE. Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations.
|
|
Expert Rev Hematol.
|
|
2017;10:81–97.
|
|
[<a href="/pmc/articles/PMC6089510/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6089510</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27929686" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27929686</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.faivre.2000.4064">Faivre
|
|
L, Guardiola
|
|
P, Lewis
|
|
C, Dokal
|
|
I, Ebell
|
|
W, Zatterale
|
|
A, Altay
|
|
C, Poole
|
|
J, Stones
|
|
D, Kwee
|
|
ML, van Weel-Sipman
|
|
M, Havenga
|
|
C, Morgan
|
|
N, de Winter
|
|
J, Digweed
|
|
M, Savoia
|
|
A, Pronk
|
|
J, de Ravel
|
|
T, Jansen
|
|
S, Joenje
|
|
H, Gluckman
|
|
E, Mathew
|
|
CG. Association of complementation group and mutation type with clinical outcome in Fanconi anemia. European Fanconi Anemia Research Group.
|
|
Blood.
|
|
2000;96:4064–70.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/11110674" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11110674</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.faivre.2005.55">Faivre
|
|
L, Portnoi
|
|
MF, Pals
|
|
G, Stoppa-Lyonnet
|
|
D, Le Merrer
|
|
M, Thauvin-Robinet
|
|
C, Huet
|
|
F, Mathew
|
|
CG, Joenje
|
|
H, Verloes
|
|
A, Baumann
|
|
C. Should chromosome breakage studies be performed in patients with VACTERL association?
|
|
Am J Med Genet A.
|
|
2005;137:55–8.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/16015582" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16015582</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.fiescoroa.2019.100589">Fiesco-Roa
|
|
MO, Giri
|
|
N, McReynolds
|
|
LJ, Fest
|
|
AF, Alter
|
|
BP. Genotype-phenotype associations in Fanconi anemia: A literature review.
|
|
Blood Rev.
|
|
2019;37:100589.
|
|
[<a href="/pmc/articles/PMC6730648/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6730648</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31351673" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31351673</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.futaki.2000.1493">Futaki
|
|
M, Yamashita
|
|
T, Yagasaki
|
|
H, Toda
|
|
T, Yabe
|
|
M, Kato
|
|
S, Asano
|
|
S, Nakahata
|
|
T.
|
|
The IVS4 + 4 A to T mutation of the Fanconi anemia gene FANCC is not associated with a severe phenotype in Japanese patients.
|
|
Blood.
|
|
2000;95:1493–8.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/10666230" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10666230</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.gandhi.2019.b16">Gandhi
|
|
M, Rac
|
|
MWF, McKinney
|
|
J, et al.
|
|
Radial ray malformation.
|
|
Am J Obstet Gynecol.
|
|
2019;221:B16–18.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/31787159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31787159</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.garciahiguera.2001.249">Garcia-Higuera
|
|
I, Taniguchi
|
|
T, Ganesan
|
|
S, Meyn
|
|
MS, Timmers
|
|
C, Hejna
|
|
J, Grompe
|
|
M, D'Andrea
|
|
AD. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway.
|
|
Mol Cell.
|
|
2001;7:249.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/11239454" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11239454</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.giardino.2020.809">Giardino
|
|
S, de Latour
|
|
RP, Aljurf
|
|
M, Eikema
|
|
DJ, Bosman
|
|
P, Bertrand
|
|
Y, Tbakhi
|
|
A, Holter
|
|
W, Bornhäuser
|
|
M, Rössig
|
|
C, Burkhardt
|
|
B, Zecca
|
|
M, Afanasyev
|
|
B, Michel
|
|
G, Ganser
|
|
A, Alseraihy
|
|
A, Ayas
|
|
M, Uckan-Cetinkaya
|
|
D, Bruno
|
|
B, Patrick
|
|
K, Bader
|
|
P, Itälä-Remes
|
|
M, Rocha
|
|
V, Jubert
|
|
C, Diaz
|
|
MA, Shaw
|
|
PJ, Junior
|
|
LGD, Locatelli
|
|
F, Kröger
|
|
N, Faraci
|
|
M, Pierri
|
|
F, Lanino
|
|
E, Miano
|
|
M, Risitano
|
|
A, Robin
|
|
M, Dufour
|
|
C, et al.
|
|
Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group.
|
|
Am J Hematol.
|
|
2020;95:809–16.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/32267023" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32267023</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.gillio.1997.105">Gillio
|
|
AP, Verlander
|
|
PC, Batish
|
|
SD, Giampietro
|
|
PF, Auerbach
|
|
AD. Phenotypic consequences of mutations in the Fanconi anemia FAC gene: an International Fanconi Anemia Registry study.
|
|
Blood.
|
|
1997;90:105–10.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/9207444" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9207444</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.giulino.2011.278">Giulino
|
|
L, Guinan
|
|
EC, Gillio
|
|
AP, Drachtman
|
|
RA, Teruya-Feldstein
|
|
J, Boulad
|
|
F. Sweet syndrome in patients with Fanconi anaemia: association with extracutaneous manifestations and progression of haematological disease.
|
|
Br J Haematol.
|
|
2011;154:278–81.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/21501135" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21501135</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.guardiola.2004.73">Guardiola
|
|
P, Socié
|
|
G, Li
|
|
X, Ribaud
|
|
P, Devergie
|
|
A, Espérou
|
|
H, Richard
|
|
P, Traineau
|
|
R, Janin
|
|
A, Gluckman
|
|
E. Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome.
|
|
Blood.
|
|
2004;103:73–7.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/12946993" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12946993</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.hartmann.2010.480">Hartmann
|
|
L, Neveling
|
|
K, Borkens
|
|
S, Schneider
|
|
H, Freund
|
|
M, Grassman
|
|
E, Theiss
|
|
S, Wawer
|
|
A, Burdach
|
|
S, Auerbach
|
|
AD, Schindler
|
|
D, Hanenberg
|
|
H, Schaal
|
|
H. Correct mRNA processing at a mutant TT splice donor in FANCC ameliorates the clinical phenotype in patients and is enhanced by delivery of suppressor U1 snRNAs.
|
|
American Journal of Human Genetics.
|
|
2010;87:480–93.
|
|
[<a href="/pmc/articles/PMC2948791/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2948791</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20869034" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20869034</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.hirsch.2004.2554">Hirsch
|
|
B, Shimamura
|
|
A, Moreau
|
|
L, Baldinger
|
|
S, Hag-alshiekh
|
|
M, Bostrom
|
|
B, Sencer
|
|
S, D'Andrea
|
|
AD. Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood.
|
|
Blood.
|
|
2004;103:2554–9.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/14670928" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14670928</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.ho.2010.552">Ho
|
|
TV, Schärer
|
|
OD. Translesion DNA synthesis polymerases in DNA interstrand crosslink repair.
|
|
Environ Mol Mutagen.
|
|
2010;51:552–66.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/20658647" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20658647</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.howlett.2002.606">Howlett
|
|
NG, Taniguchi
|
|
T, Olson
|
|
S, Cox
|
|
B, Waisfisz
|
|
Q, De Die-Smulders
|
|
C, Persky
|
|
N, Grompe
|
|
M, Joenje
|
|
H, Pals
|
|
G, Ikeda
|
|
H, Fox
|
|
EA, D'Andrea
|
|
AD. Biallelic inactivation of BRCA2 in Fanconi anemia.
|
|
Science.
|
|
2002;297:606–9.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/12065746" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12065746</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.huang.2010.926">Huang
|
|
M, D'Andrea
|
|
AD. A new nuclease member of the FAN club.
|
|
Nat Struct Mol Biol.
|
|
2010;17:926–8.
|
|
[<a href="/pmc/articles/PMC2945811/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2945811</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20683477" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20683477</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.huang.2022.389">Huang
|
|
SJ, Amendola
|
|
LM, Sternen
|
|
DL. Variation among DNA banking consent forms: points for clinicians to bank on.
|
|
J Community Genet.
|
|
2022;13:389–97.
|
|
[<a href="/pmc/articles/PMC9314484/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9314484</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35834113" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35834113</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.j_nsson.2017.519">Jónsson
|
|
H, Sulem
|
|
P, Kehr
|
|
B, Kristmundsdottir
|
|
S, Zink
|
|
F, Hjartarson
|
|
E, Hardarson
|
|
MT, Hjorleifsson
|
|
KE, Eggertsson
|
|
HP, Gudjonsson
|
|
SA, Ward
|
|
LD, Arnadottir
|
|
GA, Helgason
|
|
EA, Helgason
|
|
H, Gylfason
|
|
A, Jonasdottir
|
|
A, Jonasdottir
|
|
A, Rafnar
|
|
T, Frigge
|
|
M, Stacey
|
|
SN, Th Magnusson
|
|
O, Thorsteinsdottir
|
|
U, Masson
|
|
G, Kong
|
|
A, Halldorsson
|
|
BV, Helgason
|
|
A, Gudbjartsson
|
|
DF, Stefansson
|
|
K. Parental influence on human germline de novo mutations in 1,548 trios from Iceland.
|
|
Nature.
|
|
2017;549:519–22.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/28959963" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28959963</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.jung.2020.1588">Jung
|
|
M, Ramanagoudr-Bhojappa
|
|
R, van Twest
|
|
S, Rosti
|
|
RO, Murphy
|
|
V, Tan
|
|
W, Donovan
|
|
FX, Lach
|
|
FP, Kimble
|
|
DC, Jiang
|
|
CS, Vaughan
|
|
R, Mehta
|
|
PA, Pierri
|
|
F, Dufour
|
|
C, Auerbach
|
|
AD, Deans
|
|
AJ, Smogorzewska
|
|
A, Chandrasekharappa
|
|
SC. Association of clinical severity with FANCB variant type in Fanconi anemia.
|
|
Blood.
|
|
2020;135:1588–1602.
|
|
[<a href="/pmc/articles/PMC7193183/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7193183</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32106311" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32106311</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.kahraman.2014.340">Kahraman
|
|
S, Beyazyurek
|
|
C, Yesilipek
|
|
MA, Ozturk
|
|
G, Ertem
|
|
M, Anak
|
|
S, Kansoy
|
|
S, Aksoylar
|
|
S, Kuşkonmaz
|
|
B, Oniz
|
|
H, Slavin
|
|
S, Karakas
|
|
Z, Tac
|
|
HA, Gulum
|
|
N, Ekmekci
|
|
GC. Successful haematopoietic stem cell transplantation in 44 children from healthy siblings conceived after preimplantation HLA matching.
|
|
Reprod Biomed Online.
|
|
2014;29:340–51.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/25066893" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25066893</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.kato.2015.5234">Kato
|
|
Y, Alavattam
|
|
KG, Sin
|
|
H-S, Meetei
|
|
AR, Pang
|
|
Q, Andreassen
|
|
PR, Namekawa
|
|
SH. FANCB is essential in the male germline and regulates H3K9 methylation on the sex chromosomes during meiosis.
|
|
Hum Mol Genet.
|
|
2015;24:5234–49.
|
|
[<a href="/pmc/articles/PMC4550819/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4550819</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26123487" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26123487</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.kee.2012.3799">Kee
|
|
Y, D'Andrea
|
|
AD. Molecular pathogenesis and clinical management of Fanconi anemia.
|
|
J Clin Invest.
|
|
2012;122:3799–806.
|
|
[<a href="/pmc/articles/PMC3484428/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3484428</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23114602" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23114602</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.kim.2012.1393">Kim
|
|
H, D'Andrea
|
|
AD. Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway.
|
|
Genes Dev.
|
|
2012;26:1393–408.
|
|
[<a href="/pmc/articles/PMC3403008/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3403008</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22751496" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22751496</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.knipscheer.2009.1698">Knipscheer
|
|
P, Räschle
|
|
M, Smogorzewska
|
|
A, Enoiu
|
|
M, Ho
|
|
TV, Schärer
|
|
OD, Elledge
|
|
SJ, Walter
|
|
JC. The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair.
|
|
Science.
|
|
2009;326:1698–701.
|
|
[<a href="/pmc/articles/PMC2909596/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2909596</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19965384" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19965384</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.kutler.2016.870">Kutler
|
|
DI, Patel
|
|
K, Auerbach
|
|
A, Kennedy
|
|
J, Lach
|
|
F, Sanborn
|
|
E, Cohen
|
|
M, Kuhel
|
|
W, Smogorzewska
|
|
A. Natural history and management of Fanconi anemia patients with head and neck cancer: a 10-year follow-up.
|
|
Laryngoscope.
|
|
2016;126:870–9.
|
|
[<a href="/pmc/articles/PMC4803627/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4803627</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26484938" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26484938</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.kutler.2003.1249">Kutler
|
|
DI, Singh
|
|
B, Satagopan
|
|
J, Batish
|
|
SD, Berwick
|
|
M, Giampietro
|
|
PF, Hanenberg
|
|
H, Auerbach
|
|
AD. A 20-year perspective on the International Fanconi Anemia Registry (IFAR).
|
|
Blood.
|
|
2003;101:1249–56.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/12393516" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12393516</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.levitus.2005.934">Levitus
|
|
M, Waisfisz
|
|
Q, Godthelp
|
|
BC, de Vries
|
|
Y, Hussain
|
|
S, Wiegant
|
|
WW, Elghalbzouri-Maghrani
|
|
E, Steltenpool
|
|
J, Rooimans
|
|
MA, Pals
|
|
G, Arwert
|
|
F, Mathew
|
|
CG, Zdzienicka
|
|
MZ, Hiom
|
|
K, De Winter
|
|
JP, Joenje
|
|
H. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J.
|
|
Nat Genet.
|
|
2005;37:934–5.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/16116423" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16116423</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.levran.2005.931">Levran
|
|
O, Attwooll
|
|
C, Henry
|
|
RT, Milton
|
|
KL, Neveling
|
|
K, Rio
|
|
P, Batish
|
|
SD, Kalb
|
|
R, Velleuer
|
|
E, Barral
|
|
S, Ott
|
|
J, Petrini
|
|
J, Schindler
|
|
D, Hanenberg
|
|
H, Auerbach
|
|
AD. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia.
|
|
Nat Genet.
|
|
2005;37:931–3.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/16116424" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16116424</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.ling.2007.2104">Ling
|
|
C, Ishiai
|
|
M, Ali
|
|
AM, Medhurst
|
|
AL, Neveling
|
|
K, Kalb
|
|
R, Yan
|
|
Z, Xue
|
|
Y, Oostra
|
|
AB, Auerbach
|
|
AD, Hoatlin
|
|
ME, Schindler
|
|
D, Joenje
|
|
H, de Winter
|
|
JP, Takata
|
|
M, Meetei
|
|
AR, Wang
|
|
W. FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway.
|
|
EMBO J.
|
|
2007;26:2104–14.
|
|
[<a href="/pmc/articles/PMC1852792/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1852792</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17396147" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17396147</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.litman.2005.255">Litman
|
|
R, Peng
|
|
M, Jin
|
|
Z, Zhang
|
|
F, Zhang
|
|
J, Powell
|
|
S, Andreassen
|
|
PR, Cantor
|
|
SB. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ.
|
|
Cancer Cell.
|
|
2005;8:255–65.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/16153896" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16153896</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.macmillan.2015.3798">MacMillan
|
|
ML, DeFor
|
|
TE, Young
|
|
JA, Dusenbery
|
|
KE, Blazar
|
|
BR, Slungaard
|
|
A, Zierhut
|
|
H, Weisdorf
|
|
DJ, Wagner
|
|
JE. Alternative donor hematopoietic cell transplantation for Fanconi anemia.
|
|
Blood.
|
|
2015;125:3798–804.
|
|
[<a href="/pmc/articles/PMC4463740/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4463740</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25824692" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25824692</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.masserot.2008.3315">Masserot
|
|
C, Peffault de Latour
|
|
R, Rocha
|
|
V, Leblanc
|
|
T, Rigolet
|
|
A, Pascal
|
|
F, Janin
|
|
A, Soulier
|
|
J, Gluckman
|
|
E, Socié
|
|
G.
|
|
Head and neck squamous cell carcinoma in 13 patients with Fanconi anemia after hematopoietic stem cell transplantation.
|
|
Cancer.
|
|
2008;113:3315–22.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/18831513" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18831513</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.mccauley.2011.2370">McCauley
|
|
J, Masand
|
|
N, McGowan
|
|
R, Rajagopalan
|
|
S, Hunter
|
|
A, Michaud
|
|
JL, Gibson
|
|
K, Robertson
|
|
J, Vaz
|
|
F, Abbs
|
|
S, Holden
|
|
ST. X-linked VACTERL with hydrocephalus syndrome: further delineation of the phenotype caused by FANCB mutations.
|
|
Am J Med Genet A.
|
|
2011;155A:2370–80.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/21910217" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21910217</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.meetei.2003.3417">Meetei
|
|
AR, Sechi
|
|
S, Wallisch
|
|
M, Yang
|
|
D, Young
|
|
MK, Joenje
|
|
H, Hoatlin
|
|
ME, Wang
|
|
W. A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome.
|
|
Mol Cell Biol.
|
|
2003;23:3417–26.
|
|
[<a href="/pmc/articles/PMC164758/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC164758</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12724401" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12724401</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.mehta.2017.2308">Mehta
|
|
PA, Davies
|
|
SM, Leemhuis
|
|
T, Myers
|
|
K, Kernan
|
|
NA, Prockop
|
|
SE, Scaradavou
|
|
A, O'Reilly
|
|
RJ, Williams
|
|
DA, Lehmann
|
|
L, Guinan
|
|
E, Margolis
|
|
D, Baker
|
|
KS, Lane
|
|
A, Boulad
|
|
F. Radiation-free, alternative donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.
|
|
Blood.
|
|
2017;129:2308–15.
|
|
[<a href="/pmc/articles/PMC5766838/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5766838</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28179273" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28179273</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.mehta.2010.180">Mehta
|
|
PA, Harris
|
|
RE, Davies
|
|
SM, Kim
|
|
MO, Mueller
|
|
R, Lampkin
|
|
B, Mo
|
|
J, Myers
|
|
K, Smolarek
|
|
TA. Numerical chromosomal changes and risk of development of myelodysplastic syndrome—acute myeloid leukemia in patients with Fanconi anemia.
|
|
Cancer Genet Cytogenet.
|
|
2010;203:180–6.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/21156231" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21156231</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.mehta.2007.668">Mehta
|
|
PA, Ileri
|
|
T, Harris
|
|
RE, Williams
|
|
DA, Mo
|
|
J, Smolarek
|
|
T, Auerbach
|
|
AD, Kelly
|
|
P, Davies
|
|
SM. Chemotherapy for myeloid malignancy in children with Fanconi anemia.
|
|
Pediatr Blood Cancer.
|
|
2007;48:668–72.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/16609946" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16609946</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.mitchell.2014.384">Mitchell
|
|
R, Wagner
|
|
JE, Hirsch
|
|
B. Hematopoietic cell transplantation for acute leukaemia and advances myelodysplastic syndrome in Fanconi anemia.
|
|
Br J Haematol.
|
|
2014;164:384–95.
|
|
[<a href="/pmc/articles/PMC4060801/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4060801</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24172081" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24172081</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.morris.2011.739">Morris
|
|
LG, Sikora
|
|
AG, Patel
|
|
SG, Hayes
|
|
RB, Ganly
|
|
I. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer.
|
|
J Clin Oncol.
|
|
2011;29:739–46.
|
|
[<a href="/pmc/articles/PMC3056657/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3056657</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21189382" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21189382</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.myers.2012.462">Myers
|
|
K, Davies
|
|
SM, Harris
|
|
RE, Spunt
|
|
SL, Smolarek
|
|
T, Zimmerman
|
|
S, McMasters
|
|
R, Wagner
|
|
L, Mueller
|
|
R, Auerbach
|
|
AD, Mehta
|
|
PA. The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1/BRCA2 mutations.
|
|
Pediatr Blood Cancer.
|
|
2012;58:462–5.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/21548014" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21548014</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.nabhan.2010.1783">Nabhan
|
|
SK, Bitencourt
|
|
MA, Duval
|
|
M, Abecasis
|
|
M, Dufour
|
|
C, Boudjedir
|
|
K, Rocha
|
|
V, Socié
|
|
G, Passweg
|
|
J, Goi
|
|
K, Sanders
|
|
J, Snowden
|
|
J, Yabe
|
|
H, Pasquini
|
|
R, Gluckman
|
|
E., Aplastic Anaemia Working Party, EBMT. Fertility recovery and pregnancy after allogeneic hematopoietic stem cell transplantation in Fanconi anemia patients.
|
|
Haematologica.
|
|
2010;95:1783–7.
|
|
[<a href="/pmc/articles/PMC2948106/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2948106</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20494929" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20494929</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.nakanishi.2011.500">Nakanishi
|
|
K, Cavallo
|
|
F, Perrouault
|
|
L, Giovannangeli
|
|
C, Moynahan
|
|
ME, Barchi
|
|
M, Brunet
|
|
E, Jasin
|
|
M. Homology-directed Fanconi anemia pathway cross-link repair is dependent on DNA replication.
|
|
Nat Struct Mol Biol.
|
|
2011;18:500–3.
|
|
[<a href="/pmc/articles/PMC3273992/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3273992</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21423196" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21423196</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.nalepa.2018.168">Nalepa
|
|
G, Clapp
|
|
DW. Fanconi anaemia and cancer: an intricate relationship.
|
|
Nature Reviews Cancer.
|
|
2018;18:168–85.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/29376519" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29376519</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.neitzel.2007">Neitzel H, Kühl JS, Gerlach A, Ebell W, Tönnies H. Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients: results and implications. In: Schindler D, Hoehn H, eds. Fanconi Anemia. a Paradigmatic Disease for the Understanding of Cancer and Aging. Monographs in Human Genetics. Vol 15. Basel: Karger. 2007:79-94.</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.niraj.2019.457">Niraj
|
|
J, Färkkilä
|
|
A, D'Andrea
|
|
AD. The Fanconi anemia pathway in cancer.
|
|
Annu Rev Cancer Biol.
|
|
2019;3:457–78.
|
|
[<a href="/pmc/articles/PMC6417835/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6417835</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30882047" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30882047</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.paustian.2016.5">Paustian
|
|
L, Chao
|
|
MM, Hanenberg
|
|
H, Schindler
|
|
D, Neitzel
|
|
H, Kratz
|
|
CP, Ebell
|
|
W. Androgen therapy in Fanconi anemia: a retrospective analysis of 30 years in Germany.
|
|
Pediatr Hematol Oncol.
|
|
2016;33:5–12.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/26900943" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26900943</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.petryk.2015.803">Petryk
|
|
A, Shaker
|
|
RK, Giri
|
|
N, Hollenberg
|
|
AN, Rutter
|
|
MM, Nathan
|
|
B, Lodish
|
|
M, Alter
|
|
BP, Stratakis
|
|
CA, Rose
|
|
SR. Endocrine disorders in Fanconi Anemia: Recommendations from Screening and Treatment.
|
|
J Clin Endocrinol Metab.
|
|
2015;100:803–11.
|
|
[<a href="/pmc/articles/PMC4333044/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4333044</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25575015" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25575015</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.rahbari.2016.126">Rahbari
|
|
R, Wuster
|
|
A, Lindsay
|
|
SJ, Hardwick
|
|
RJ, Alexandrov
|
|
LB, Turki
|
|
SA, Dominiczak
|
|
A, Morris
|
|
A, Porteous
|
|
D, Smith
|
|
B, Stratton
|
|
MR, Hurles
|
|
ME, et al.
|
|
Timing, rates and spectra of human germline mutation.
|
|
Nat Genet.
|
|
2016;48:126–33.
|
|
[<a href="/pmc/articles/PMC4731925/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4731925</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26656846" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26656846</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.rechitsky.2020.220">Rechitsky
|
|
S, Kuliev
|
|
A, San Ramon
|
|
G, Tur-Kaspa
|
|
I, Wang
|
|
Y, Wang
|
|
W, Wu
|
|
X, Wang
|
|
L, Leigh
|
|
D, Cram
|
|
DS. Single-molecule sequencing: A new approach for preimplantation testing and noninvasive prenatal diagnosis confirmation of fetal genotype.
|
|
J Mol Diagn.
|
|
2020;22:220–7.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/31751677" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31751677</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.reid.2007.162">Reid
|
|
S, Schindler
|
|
D, Hanenberg
|
|
H, Barker
|
|
K, Hanks
|
|
S, Kalb
|
|
R, Neveling
|
|
K, Kelly
|
|
P, Seal
|
|
S, Freund
|
|
M, Wurm
|
|
M, Batish
|
|
SD, Lach
|
|
FP, Yetgin
|
|
S, Neitzel
|
|
H, Ariffin
|
|
H, Tischkowitz
|
|
M, Mathew
|
|
CG, Auerbach
|
|
AD, Rahman
|
|
N. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer.
|
|
Nat Genet.
|
|
2007;39:162–4.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/17200671" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17200671</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.richards.2015.405">Richards
|
|
S, Aziz
|
|
N, Bale
|
|
S, Bick
|
|
D, Das
|
|
S, Gastier-Foster
|
|
J, Grody
|
|
WW, Hegde
|
|
M, Lyon
|
|
E, Spector
|
|
E, Voelkerding
|
|
K, Rehm
|
|
HL, et al.
|
|
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
|
|
Genet Med.
|
|
2015;17:405–24.
|
|
[<a href="/pmc/articles/PMC4544753/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4544753</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25741868" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25741868</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.r_o.2017.1535">Río
|
|
P, Navarro
|
|
S, Guenechea
|
|
G, Sánchez-Domínguez
|
|
R, Lamana
|
|
ML, Yañez
|
|
R, Casado
|
|
JA, Mehta
|
|
PA, Pujol
|
|
MR, Surrallés
|
|
J, Charrier
|
|
S, Galy
|
|
A, Segovia
|
|
JC, Díaz de Heredia
|
|
C, Sevilla
|
|
J, Bueren
|
|
JA. Engraftment and in vivo proliferation advantage of gene-corrected mobilized CD34(+) cells from Fanconi anemia patients.
|
|
Blood.
|
|
2017;130:1535–42.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/28801449" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28801449</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.rose.2014.11">Rose
|
|
SR, Kim
|
|
MO, Korbee
|
|
L, Wilson
|
|
KA, Douglas Ris
|
|
M, Eyal
|
|
O, Sherafat-Kazemzadeh
|
|
R, Bollepalli
|
|
S, Harris
|
|
R, Jeng
|
|
MR, Williams
|
|
DA, Smith
|
|
FO. Oxandrolone for the treatment of bone marrow failure in Fanconi anemia.
|
|
Pediatr Blood Cancer.
|
|
2014;61:11–9.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/24019220" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24019220</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.rosenberg.2008.511">Rosenberg
|
|
PS, Alter
|
|
BP, Ebell
|
|
W. Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry.
|
|
Haematologica.
|
|
2008;93:511–7.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/18322251" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18322251</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.rosenberg.2005.67">Rosenberg
|
|
PS, Socié
|
|
G, Alter
|
|
BP, Gluckman
|
|
E. Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants.
|
|
Blood.
|
|
2005;105:67–73.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15331448" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15331448</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.rosenberg.2011.1877">Rosenberg
|
|
PS, Tamary
|
|
H, Alter
|
|
BP. How high are carrier frequencies of rare recessive syndromes? Contemporary estimates for Fanconi Anemia in the United States and Israel.
|
|
Am J Med Genet A.
|
|
2011;155A:1877–83.
|
|
[<a href="/pmc/articles/PMC3140593/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3140593</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21739583" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21739583</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.scheckenbach.2012.128">Scheckenbach
|
|
K, Morgan
|
|
M, Filger-Brillinger
|
|
J, Sandmann
|
|
M, Strimling
|
|
B, Scheurlen
|
|
W, Schindler
|
|
D, Göbel
|
|
U, Hanenberg
|
|
H. Treatment of the bone marrow failure in Fanconi anemia patients with danazol.
|
|
Blood Cells Mol Dis.
|
|
2012;48:128–31.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/22178060" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22178060</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.seal.2006.1239">Seal
|
|
S, Thompson
|
|
D, Renwick
|
|
A, Elliott
|
|
A, Kelly
|
|
P, Barfoot
|
|
R, Chagtai
|
|
T, Jayatilake
|
|
H, Ahmed
|
|
M, Spanova
|
|
K, North
|
|
B, McGuffog
|
|
L, Evans
|
|
DG, Eccles
|
|
D, Easton
|
|
DF, Stratton
|
|
MR, Rahman
|
|
N, et al.
|
|
Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.
|
|
Nat Genet.
|
|
2006;38:1239–41.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/17033622" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17033622</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.shimamura.2010.101">Shimamura
|
|
A, Alter
|
|
BP. Pathophysiology and management of inherited bone marrow failure syndromes.
|
|
Blood Rev.
|
|
2010;24:101–22.
|
|
[<a href="/pmc/articles/PMC3733544/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3733544</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20417588" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20417588</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.smogorzewska.2007.289">Smogorzewska
|
|
A, Matsuoka
|
|
S, Vinciguerra
|
|
P, McDonald
|
|
ER
|
|
3rd, Hurov
|
|
KE, Luo
|
|
J, Ballif
|
|
BA, Gygi
|
|
SP, Hofmann
|
|
K, D'Andrea
|
|
AD, Elledge
|
|
SJ. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair.
|
|
Cell.
|
|
2007;129:289–301.
|
|
[<a href="/pmc/articles/PMC2175179/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2175179</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17412408" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17412408</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.song.2010.31525">Song
|
|
IY, Palle
|
|
K, Gurkar
|
|
A, Tateishi
|
|
S, Kupfer
|
|
GM, Vaziri
|
|
C. Rad18-mediated translesion synthesis of bulky DNA adducts is coupled to activation of the Fanconi anemia DNA repair pathway.
|
|
J Biol Chem.
|
|
2010;285:31525–36.
|
|
[<a href="/pmc/articles/PMC2951227/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2951227</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20675655" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20675655</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.spanier.2012.510">Spanier
|
|
G, Pohl
|
|
F, Giese
|
|
T, Meier
|
|
JK, Koelbl
|
|
O, Reichert
|
|
TE. Fatal course of tonsillar squamous cell carcinoma associated with Fanconi anaemia: a mini review.
|
|
J Craniomaxillofac Surg.
|
|
2012;40:510–5.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/21925890" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21925890</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.stenson.2020.1197">Stenson
|
|
PD, Mort
|
|
M, Ball
|
|
EV, Chapman
|
|
M, Evans
|
|
K, Azevedo
|
|
L, Hayden
|
|
M, Heywood
|
|
S, Millar
|
|
DS, Phillips
|
|
AD, Cooper
|
|
DN. The Human Gene Mutation Database (HGMD®): optimizing its use in a clinical diagnostic or research setting.
|
|
Hum Genet.
|
|
2020;139:1197–207.
|
|
[<a href="/pmc/articles/PMC7497289/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7497289</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32596782" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32596782</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.strocchio.2021.1333">Strocchio
|
|
L, Pagliara
|
|
D, Algeri
|
|
M, Li Pira
|
|
G, Rossi
|
|
F, Bertaina
|
|
V, Leone
|
|
G, Pinto
|
|
RM, Andreani
|
|
M, Agolini
|
|
E, Girardi
|
|
K, Gaspari
|
|
S, Grapulin
|
|
L, Del Bufalo
|
|
F, Novelli
|
|
A, Merli
|
|
P, Locatelli
|
|
F. HLA-haploidentical TCRalphabeta+/CD19+-depleted stem cell transplantation in children and young adults with Fanconi anemia.
|
|
Blood Adv.
|
|
2021;5:1333–9.
|
|
[<a href="/pmc/articles/PMC7948273/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7948273</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33656536" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33656536</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.talbot.2014.e199">Talbot
|
|
A, Peffault de Latour
|
|
R, Raffoux
|
|
E, Buchbinder
|
|
N, Vigouroux
|
|
S, Milpied
|
|
N, Leblanc
|
|
T, Soulier
|
|
J, Michallet
|
|
M, Socié
|
|
G.
|
|
Sequential treatment for allogeneic hematopoietic stem cell transplantation in Fanconi anemia with acute myeloid leukemia.
|
|
Haematologica.
|
|
2014;99:e199–200.
|
|
[<a href="/pmc/articles/PMC4181270/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4181270</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25085358" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25085358</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.tamary.2010.1300">Tamary
|
|
H, Nishri
|
|
D, Yacobovich
|
|
J, Zilber
|
|
R, Dgany
|
|
O, Krasnov
|
|
T, Aviner
|
|
S, Stepensky
|
|
P, Ravel-Vilk
|
|
S, Bitan
|
|
M, Kaplinsky
|
|
C, Ben Barak
|
|
A, Elhasid
|
|
R, Kapelusnik
|
|
J, Koren
|
|
A, Levin
|
|
C, Attias
|
|
D, Laor
|
|
R, Yaniv
|
|
I, Rosenberg
|
|
PS, Alter
|
|
BP. Frequency and natural history of inherited bone marrow failure syndromes: the Israeli Inherited Bone Marrow Failure Registry.
|
|
Haematologica.
|
|
2010;95:1300–7.
|
|
[<a href="/pmc/articles/PMC2913078/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2913078</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20435624" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20435624</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.tan.2011.e591">Tan
|
|
IB, Cutcutache
|
|
I, Zang
|
|
ZJ, Iqbal
|
|
J, Yap
|
|
SF, Hwang
|
|
W, Lim
|
|
WT, Teh
|
|
BT, Rozen
|
|
S, Tan
|
|
EH, Tan
|
|
P. Fanconi's anemia in adulthood: chemoradiation-induced bone marrow failure and a novel FANCA mutation identified by targeted deep sequencing.
|
|
J Clin Oncol.
|
|
2011;29:e591–4.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/21519011" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21519011</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.taniguchi.2006.4223">Taniguchi
|
|
T, D'Andrea
|
|
AD. Molecular pathogenesis of Fanconi anemia: recent progress.
|
|
Blood.
|
|
2006;107:4223–33.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/16493006" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16493006</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.tsui.2019.199">Tsui
|
|
V, Crismani
|
|
W.
|
|
The Fanconi anemia pathway and fertility.
|
|
Trends Genet.
|
|
2019;35:199–214.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/30683429" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30683429</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.wagner.2004.3226">Wagner
|
|
JE, Tolar
|
|
J, Levran
|
|
O, Scholl
|
|
T, Deffenbaugh
|
|
A, Satagopan
|
|
J, Ben-Porat
|
|
L, Mah
|
|
K, Batish
|
|
SD, Kutler
|
|
DI, MacMillan
|
|
ML, Hanenberg
|
|
H, Auerbach
|
|
AD. Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia.
|
|
Blood.
|
|
2004;103:3226–9.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15070707" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15070707</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.williams.2011.4395">Williams
|
|
SA, Wilson
|
|
JB, Clark
|
|
AP, Mitson-Salazar
|
|
A, Tomashevski
|
|
A, Ananth
|
|
S, Glazer
|
|
PM, Semmes
|
|
OJ, Bale
|
|
AE, Jones
|
|
NJ, Kupfer
|
|
GM. Functional and physical interaction between the mismatch repair and FA-BRCA pathways.
|
|
Hum Mol Genet.
|
|
2011;20:4395–410.
|
|
[<a href="/pmc/articles/PMC3196888/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3196888</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21865299" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21865299</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.wilson.2010.12">Wilson
|
|
JB, Blom
|
|
E, Cunningham
|
|
R, Xiao
|
|
Y, Kupfer
|
|
GM, Jones
|
|
NJ. Several tetratricopeptide repeat (TPR) motifs of FANCG are required for assembly of the BRCA2/D1-D2-G-X3 complex, FANCD2 monoubiquitylation and phleomycin resistance.
|
|
Mutat Res.
|
|
2010;689:12–20.
|
|
[<a href="/pmc/articles/PMC2903733/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2903733</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20450923" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20450923</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.xia.2006.719">Xia
|
|
B, Sheng
|
|
Q, Nakanishi
|
|
K, Ohashi
|
|
A, Wu
|
|
J, Christ
|
|
N, Liu
|
|
X, Jasin
|
|
M, Couch
|
|
FJ, Livingston
|
|
DM. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.
|
|
Mol Cell.
|
|
2006;22:719–29.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/16793542" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16793542</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.yamashita.1996.4424">Yamashita
|
|
T, Wu
|
|
N, Kupfer
|
|
G, Corless
|
|
C, Joenje
|
|
H, Grompe
|
|
M, D'Andrea
|
|
AD. The Clinical variability of Fanconi Anemia (Type C) results from expression of an amino terminal truncated FAC polypeptide with partial activity.
|
|
Blood.
|
|
1996;87:4424.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/8639804" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8639804</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.zhang.2010.637">Zhang
|
|
F, Fan
|
|
Q, Ren
|
|
K, Auerbach
|
|
AD, Andreassen
|
|
PR. FANCJ/BRIP1 recruitment and regulation of FANCD2 in DNA damage responses.
|
|
Chromosoma.
|
|
2010;119:637–49.
|
|
[<a href="/pmc/articles/PMC4928586/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4928586</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20676667" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20676667</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.zhang.2015.90">Zhang
|
|
QS, Benedetti
|
|
E, Deater
|
|
M, Schubert
|
|
K, Major
|
|
A, Pelz
|
|
C, Impey
|
|
S, Marquez-Loza
|
|
L, Rathbun
|
|
RK, Kato
|
|
S, Bagby
|
|
GC, Grompe
|
|
M. Oxymetholone therapy of fanconi anemia suppresses osteopontin transcription and induces hematopoietic stem cell cycling.
|
|
Stem Cell Reports.
|
|
2015;4:90–102.
|
|
[<a href="/pmc/articles/PMC4297866/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4297866</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25434823" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25434823</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.zheng.2021.415">Zheng
|
|
K, Liu
|
|
T, Zhao
|
|
J, Meng
|
|
P, Bian
|
|
Y, Ni
|
|
C, Wang
|
|
H, Pan
|
|
Y, Wu
|
|
S, Jiang
|
|
H, Jin
|
|
G. Mutational landscape and potential therapeutic targets for sporadic pancreatic neuroendocrine tumors based on target next-generation sequencing.
|
|
Exp Ther Med.
|
|
2021;21:415.
|
|
[<a href="/pmc/articles/PMC7967861/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7967861</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33747156" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33747156</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.zhi.2009.8775">Zhi
|
|
G, Wilson
|
|
JB, Chen
|
|
X, Krause
|
|
DS, Xiao
|
|
Y, Jones
|
|
NJ, Kupfer
|
|
GM. Fanconi anemia complementation group FANCD2 protein serine 331 phosphorylation is important for Fanconi anemia pathway function and BRCA2 interaction.
|
|
Cancer Res.
|
|
2009;69:8775–83.
|
|
[<a href="/pmc/articles/PMC5912675/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5912675</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19861535" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19861535</span></a>]</div></p></li><li class="half_rhythm"><p><div class="bk_ref" id="fa.REF.zubicaray.2021.571">Zubicaray
|
|
J, Pagliara
|
|
D, Sevilla
|
|
J, Eikema
|
|
DJ, Bosman
|
|
P, Ayas
|
|
M, Zecca
|
|
M, Yesilipek
|
|
A, Kansoy
|
|
S, Renard
|
|
C, Dalle
|
|
JH, Campos
|
|
A, Faraci
|
|
M, Kupesiz
|
|
A, Smiers
|
|
FJW, Velardi
|
|
A, Abecasis
|
|
M, Corti
|
|
P, Fagioli
|
|
F, González Muñiz
|
|
S, Kriván
|
|
G, Dufour
|
|
C, Risitano
|
|
A, Corbacioglu
|
|
S, Peffault de Latour
|
|
R. Haplo-identical or mismatched unrelated donor hematopoietic cell transplantation for Fanconi anemia: Results from the Severe Aplastic Anemia Working Party of the EBMT.
|
|
Am J Hematol.
|
|
2021;96:571–9.
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/33606297" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33606297</span></a>]</div></p></li></ul></div></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK1401_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><div class="contrib half_rhythm"><span itemprop="author">Parinda A Mehta</span>, MD<div class="affiliation small">Professor, Division of Bone Marrow Transplantation and Immune Deficiency<br />Cincinnati Children's Hospital Medical Center<br />Cincinnati, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.cmhcc@athem.adnirap" class="oemail">gro.cmhcc@athem.adnirap</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Christen Ebens</span>, MD, MPH<div class="affiliation small">Assistant Professor, Division of Blood and Marrow Transplant & Cellular Therapy<br />University of Minnesota<br />Minneapolis, Minnesota<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.nmu@210snebe" class="oemail">ude.nmu@210snebe</a></div></div></div><h3>Publication History</h3><p class="small">Initial Posting: <span itemprop="datePublished">February 14, 2002</span>; Last Update: <span itemprop="dateModified">June 3, 2021</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2025, University of Washington, Seattle. GeneReviews is
|
|
a registered trademark of the University of Washington, Seattle. All rights
|
|
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
|
|
hereby granted to reproduce, distribute, and translate copies of content materials for
|
|
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2025 University of
|
|
Washington) are included with each copy; (ii) a link to the original material is provided
|
|
whenever the material is published elsewhere on the Web; and (iii) reproducers,
|
|
distributors, and/or translators comply with the <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/GRcopyright_permiss/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">GeneReviews® Copyright Notice and Usage
|
|
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
|
|
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
|
|
use.</p><p class="small">For more information, see the <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/GRcopyright_permiss/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">GeneReviews® Copyright Notice and Usage
|
|
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
|
|
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div></div><h3>Publisher</h3><p><a href="http://www.washington.edu" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">University of Washington, Seattle</a>, Seattle (WA)</p><h3>NLM Citation</h3><p>Mehta PA, Ebens C. Fanconi Anemia. 2002 Feb 14 [Updated 2021 Jun 3]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/gene/porphyria-ct/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/gene/fahn/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobfaTmoleculargenetictestingusedinf"><div id="fa.T.molecular_genetic_testing_used_in_f" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Fanconi Anemia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1401/table/fa.T.molecular_genetic_testing_used_in_f/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fa.T.molecular_genetic_testing_used_in_f_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene <sup>1, 2</sup></th><th id="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" style="text-align:left;vertical-align:middle;">Complementation Group <sup>3</sup></th><th id="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" style="text-align:left;vertical-align:middle;">% of FA Attributed to Pathogenic Variants in Gene <sup>4</sup></th><th id="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants <sup>5</sup> Detected by Method</th></tr><tr><th headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4" id="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis <sup>6</sup></th><th headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4" id="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted deletion/duplication analysis <sup>7</sup></th></tr></thead><tbody><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>BRCA1</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-S</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><1%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>99%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>BRCA2</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-D1</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>99%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>BRIP1</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-J</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>99%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>ERCC4</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-Q</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><1%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>99%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>FAAP100</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-Y</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 individual <sup>8</sup></td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>99%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>FANCA</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-A</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">60%-70%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~60%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~40%</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>FANCB</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-B</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~70%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~30%</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>FANCC</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-C</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">14%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>90%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><10%</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>FANCD2</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-D2</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><90%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>10%</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>FANCE</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-E</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>99%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>FANCF</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-F</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~85%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~15%</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FANCG</i> (<i>XRCC9</i>)</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-G</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>99%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>FANCI</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-I</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>95%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><5%</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>FANCL</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-L</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><1%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>90%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><10%</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>FANCM</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-M</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><1%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~75%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 reported</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>PALB2</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-N</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><1%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>95%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 reported</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>RAD51</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-R</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2 reported</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>99%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>RAD51C</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-O</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><1%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>99%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>REV7 (MAD2L2)</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-V</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 reported</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>99%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>RFWD3</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-W</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 reported</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>99%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>SLX4</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-P</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><1%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>90%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 reported</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>UBE2T</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-T</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><1%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><50%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>50%</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>XRCC2</i>
|
|
</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FA-U</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 reported</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">>99%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported</td></tr><tr><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><5%</td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_1_4 hd_h_fa.T.molecular_genetic_testing_used_in_f_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">NA = not applicable</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="fa.TF.1.1"><p class="no_margin">Genes are listed in alphabetic order.</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="fa.TF.1.2"><p class="no_margin">See <a href="/books/NBK1401/?report=reader#fa.molgen.TA">Table A. Genes and Databases</a> for chromosome locus and protein.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3. </dt><dd><div id="fa.TF.1.3"><p class="no_margin">Prior to identification of the genes, complementation groups were defined based on somatic cell-based methods. While complementation analysis testing has been supplanted by multigene panels; this terminology continues to be used in some contexts.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4. </dt><dd><div id="fa.TF.1.4"><p class="no_margin">Data derived from the subscription-based professional view of Human Gene Mutation Database [<a class="bibr" href="#fa.REF.stenson.2020.1197" rid="fa.REF.stenson.2020.1197">Stenson et al 2020</a>]</p></div></dd></dl><dl class="bkr_refwrap"><dt>5. </dt><dd><div id="fa.TF.1.5"><p class="no_margin">See <a href="#fa.Molecular_Genetics"><u>Molecular Genetics</u></a> for information on pathogenic variants detected in these genes.</p></div></dd></dl><dl class="bkr_refwrap"><dt>6. </dt><dd><div id="fa.TF.1.6"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include missense, nonsense, and splice site variants small intragenic deletions/insertions; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <a href="/books/n/gene/app2/?report=reader">here</a>.</p></div></dd></dl><dl class="bkr_refwrap"><dt>7. </dt><dd><div id="fa.TF.1.7"><p class="no_margin">Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include a range of techniques such as quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p></div></dd></dl><dl class="bkr_refwrap"><dt>8. </dt><dd><div id="fa.TF.1.8"><p class="no_margin">Author, personal communication</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobfaTseverityofbonemarrowfailurein"><div id="fa.T.severity_of_bone_marrow_failure_in" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Severity of Bone Marrow Failure in Fanconi Anemia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1401/table/fa.T.severity_of_bone_marrow_failure_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fa.T.severity_of_bone_marrow_failure_in_lrgtbl__"><table><thead><tr><th id="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></th><th id="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild</th><th id="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Moderate</th><th id="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe</th></tr></thead><tbody><tr><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Absolute neutrophil count (ANC)</b>
|
|
</td><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><1,500/mm<sup>3</sup></td><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><1,000/mm<sup>3</sup></td><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><500/mm<sup>3</sup></td></tr><tr><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Platelet count</b>
|
|
</td><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">150,000-50,000/mm<sup>3</sup></td><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><50,000/mm<sup>3</sup></td><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><30,000/mm<sup>3</sup></td></tr><tr><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Hemoglobin (Hb) level</b>
|
|
</td><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">≥8 g/dL</td><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><8 g/dL</td><td headers="hd_h_fa.T.severity_of_bone_marrow_failure_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><8 g/dL</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobfaTallelicdisorders"><div id="fa.T.allelic_disorders" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Allelic Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1401/table/fa.T.allelic_disorders/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fa.T.allelic_disorders_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fa.T.allelic_disorders_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_fa.T.allelic_disorders_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_fa.T.allelic_disorders_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Disorder</th></tr></thead><tbody><tr><td headers="hd_h_fa.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>BRCA1</i>
|
|
</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Hereditary breast & ovarian cancer (See <a href="/books/n/gene/brca1/?report=reader"><i>BRCA1</i>- and <i>BRCA2</i>-Associated Hereditary Breast and Ovarian Cancer</a>.)<br />Pancreatic cancer (OMIM <a href="https://omim.org/entry/613347" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">613347</a> & <a href="https://omim.org/entry/614320" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">614320</a>)<br />Prostate cancer (OMIM <a href="https://omim.org/entry/176807" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">176807</a>)</td></tr><tr><td headers="hd_h_fa.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>BRCA2</i>
|
|
</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td></tr><tr><td headers="hd_h_fa.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>BRIP1</i>
|
|
</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Breast cancer & ovarian cancer predisposition (OMIM <a href="https://omim.org/entry/605882" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">605882</a> & OMIM <a href="https://omim.org/entry/167000" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">167000</a>)</td></tr><tr><td headers="hd_h_fa.T.allelic_disorders_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>ERCC4</i>
|
|
</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/xp/?report=reader">Xeroderma pigmentosum</a>
|
|
</td></tr><tr><td headers="hd_h_fa.T.allelic_disorders_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Individuals reported w/phenotypes of Fanconi anemia, xeroderma pigmentosum (XP)/Cockayne Syndrome (CS) complex or w/combined XP/CS/Fanconi anemia (OMIM <a href="https://omim.org/entry/278760" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">278760</a>)</td></tr><tr><td headers="hd_h_fa.T.allelic_disorders_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XFE progeroid syndrome (OMIM <a href="https://omim.org/entry/610965" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">610965</a>)</td></tr><tr><td headers="hd_h_fa.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>FANCA</i>
|
|
</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Breast cancer & ovarian cancer predisposition [<a class="bibr" href="#fa.REF.del_valle.2020.829" rid="fa.REF.del_valle.2020.829">Del Valle et al 2020</a>]</td></tr><tr><td headers="hd_h_fa.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>FANCM</i>
|
|
</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Spermatogenic failure; premature ovarian failure (OMIM <a href="https://omim.org/entry/618086" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">618086</a> & <a href="https://omim.org/entry/618096" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">618096</a>)</td></tr><tr><td headers="hd_h_fa.T.allelic_disorders_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>PALB2</i>
|
|
</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Breast cancer & ovarian cancer predisposition (OMIM <a href="https://omim.org/entry/114480" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">114480</a>)</td></tr><tr><td headers="hd_h_fa.T.allelic_disorders_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pancreatic cancer predisposition (OMIM <a href="https://omim.org/entry/613348" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">613348</a>)</td></tr><tr><td headers="hd_h_fa.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>RAD51</i>
|
|
</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/mirror/?report=reader">Congenital mirror movements</a>
|
|
</td></tr><tr><td headers="hd_h_fa.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>RAD51C</i>
|
|
</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Breast cancer & ovarian cancer susceptibility (OMIM <a href="https://omim.org/entry/613399" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">613399</a>)</td></tr><tr><td headers="hd_h_fa.T.allelic_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>XRCC2</i>
|
|
</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_fa.T.allelic_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Spermatogenic failure; premature ovarian failure (OMIM <a href="https://omim.org/entry/619145" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">619145</a> & <a href="https://omim.org/entry/619146" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">619146</a>)</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">AD = autosomal dominant; AR = autosomal recessive; MOI = mode of inheritance</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobfaTgenesanddisordersofinterestin"><div id="fa.T.genes_and_disorders_of_interest_in" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Genes and Disorders of Interest in the Differential Diagnosis of Fanconi Anemia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1401/table/fa.T.genes_and_disorders_of_interest_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fa.T.genes_and_disorders_of_interest_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chromosome Breakage</th><th id="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical Characteristics</th></tr></thead><tbody><tr><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>ATM</i>
|
|
</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/ataxia-telangiectas/?report=reader">Ataxia-telangiectasia</a> (A-T)</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cells derived from persons w/A-T may exhibit high rates of spontaneous chromosome breakage.</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progressive cerebellar ataxia, oculomotor apraxia, choreoathetosis, conjunctival telangiectasias, immunodeficiency, frequent infections, ↑ risk for malignancy, hypersensitivity to ionizing radiation</td></tr><tr><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ATR</i><br /><i>CPAP</i> (<i>CENPJ</i>)<br /><i>CEP152</i><br /><i>CEP63</i><br /><i>DNA2</i><br /><i>NIN</i><br /><i>NSMCE2</i><br /><i>RBBP8</i><br /><i>TRAIP</i></td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Seckel syndrome (OMIM <a href="https://omim.org/phenotypicSeries/PS210600" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PS210600</a>)</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">May show ↑ chromosome breakage w/DNA cross-linking agents <sup>1</sup> (MMC, DEB)</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Growth deficiency, microcephaly w/ID, characteristic facial appearance; may be assoc w/pancytopenia &/or AML</td></tr><tr><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>BLM</i>
|
|
</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/bloom/?report=reader">Bloom syndrome</a> (BSyn)</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cells derived from persons w/BSyn may exhibit high rates of spontaneous chromosome breakage.</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe pre- & postnatal growth deficiency, immune abnormalities, sensitivity to sunlight, insulin resistance, high risk for many cancers that occur at an early age</td></tr><tr><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>NBN</i>
|
|
</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/nijmegen/?report=reader">Nijmegen breakage syndrome</a>
|
|
</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">May manifest ↑ chromosome breakage w/MMC</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Short stature, progressive microcephaly w/loss of cognitive skills, premature ovarian failure in females, recurrent sinopulmonary infections, ↑ risk for cancer (esp lymphoma)</td></tr><tr><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>NF1</i>
|
|
</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/nf1/?report=reader">Neurofibromatosis 1</a>
|
|
</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not assoc w/↑ chromosome breakage</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Multiple café au lait spots, axillary & inguinal freckling, multiple cutaneous neurofibromas, iris Lisch nodules, choroidal freckling</td></tr><tr><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>RBM8A</i> <sup>2</sup></td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="/books/n/gene/tar/?report=reader">Thrombocytopenia absent radius syndrome</a>
|
|
</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not assoc w/chromosome breakage</td><td headers="hd_h_fa.T.genes_and_disorders_of_interest_in_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bilateral absence of the radii w/presence of both thumbs & thrombocytopenia that is generally transient</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">AD = autosomal dominant; AR = autosomal recessive; DEB = diepoxybutane; FA = Fanconi anemia; ID = intellectual disability; MMC = mitomycin C; MOI = mode of inheritance</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="fa.TF.4.1"><p class="no_margin">
|
|
<a class="bibr" href="#fa.REF.andreassen.2004.1958" rid="fa.REF.andreassen.2004.1958">Andreassen et al [2004]</a>
|
|
</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="fa.TF.4.2"><p class="no_margin">The diagnosis of thrombocytopenia absent radius syndrome is confirmed by identification of a null heterozygous allele (most often a minimally deleted 200-kb region at chromosome band 1q21.1, but in some cases a heterozygous <i>RBM8A</i> pathogenic variant detected by molecular genetic testing) in <i>trans</i> with a heterozygous <i>RBM8A</i> hypomorphic allele.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobfaTrecommendedevaluationsfollowingi"><div id="fa.T.recommended_evaluations_following_i" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Recommended Evaluations Following Initial Diagnosis in Individuals with Fanconi Anemia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1401/table/fa.T.recommended_evaluations_following_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fa.T.recommended_evaluations_following_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Growth</b>
|
|
</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Growth assessment; exam by endocrinologist</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Additional studies (growth hormone levels, bone age radiographs) as recommended by endocrinologist</td></tr><tr><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Musculoskeletal</b>
|
|
</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical assessment for limb anomalies, hip dislocation, neck/spine anomalies & scoliosis</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Referral to orthopedic surgeon as indicated</td></tr><tr><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Eyes</b>
|
|
</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Exam by ophthalmologist</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Genitourinary</b>
|
|
</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ultrasound exam of kidneys & urinary tract</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Referral to nephrologist, gynecologist &/or urologist as indicated</td></tr><tr><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Endocrine</b>
|
|
</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Exam by endocrinologist; thyroid function tests; brain MRI for pituitary abnormalities</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Additional studies (glucose tolerance testing, lipids, pituitary & gonadal function testing) as recommended by endocrinologist</td></tr><tr><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Hearing</b>
|
|
</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Formal hearing eval</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Referral to otolaryngologist as indicated</td></tr><tr><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Cardiac/</b>
|
|
<br />
|
|
<b>Vascular</b>
|
|
</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Echocardiogram; brain MRI & angiography for moyamoya disease</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Referral to cardiologist as indicated</td></tr><tr><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Gastrointestinal</b>
|
|
</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Urgent eval w/gastroenterologist & surgery for those w/obstructive GI malformations (e.g., esophageal atresia, duodenal atresia, or imperforate or bifurcated anus) &/or tracheoesophageal fistula, intestinal malrotation, or annular pancreas</div></li><li class="half_rhythm"><div>Nutrition/feeding eval as needed</div></li></ul>
|
|
</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Referral to gastroenterologist, dietician, & surgeon as indicated</td></tr><tr><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Development</b>
|
|
</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Developmental assessment (esp important for toddlers & school-age children)</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Referral to neuropsychologist or developmental/behavioral pediatrician as indicated</td></tr><tr><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Hematology/</b>
|
|
<br />
|
|
<b>Oncology</b>
|
|
</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Eval by hematologist incl complete blood count, fetal hemoglobin, full blood typing, blood chemistries (assessing liver, kidney, & iron status), & bone marrow aspirate for cell morphology, FISH & cytogenetics, & biopsy for cellularity</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">The bone marrow of those w/FA can exhibit signs of dysplasia, e.g., nuclear/cytoplasmic dys-synchrony, hypo-lobulated megakaryocytes, & bi-nucleated erythroid cells. These features must be distinguished from true forms of MDS by a hematopathologist experienced in eval of MDS in those w/FA.</td></tr><tr><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">HLA typing of the affected person, sibs, & parents for consideration of hematopoietic stem cell transplantation</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Genetic</b>
|
|
<br />
|
|
<b>counseling</b>
|
|
</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">By genetics professionals <sup>1</sup></td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To obtain a pedigree & inform affected persons & families re nature, MOI, & implications of FA to facilitate medical & personal decision making</td></tr><tr><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Family support</b>
|
|
<br />
|
|
<b>& resources</b>
|
|
</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess need for:
|
|
<ul><li class="half_rhythm"><div>Community or <a href="#fa.Resources">online resources</a> such as <a href="https://www.p2pusa.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Parent to Parent</a>;</div></li><li class="half_rhythm"><div>Social work involvement for parental support;</div></li><li class="half_rhythm"><div>Home nursing referral.</div></li></ul>
|
|
</td><td headers="hd_h_fa.T.recommended_evaluations_following_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">FA = Fanconi anemia; GI = gastrointestinal; HLA = human leukocyte antigen; MOI = mode of inheritance; MDS = myelodysplastic syndrome</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="fa.TF.5.1"><p class="no_margin">Medical geneticist, certified genetic counselor, certified advanced genetic nurse</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobfaTtreatmentofmanifestationsinindi"><div id="fa.T.treatment_of_manifestations_in_indi" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Treatment of Manifestations in Individuals with Fanconi Anemia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1401/table/fa.T.treatment_of_manifestations_in_indi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fa.T.treatment_of_manifestations_in_indi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation/Concern</th><th id="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Growth deficiency</b>
|
|
</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment per endocrinologist</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Limb anomalies &</b>
|
|
<br />
|
|
<b>other orthopedic</b>
|
|
<br />
|
|
<b>manifestations</b>
|
|
</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Mgmt per orthopedic surgeon</div></li><li class="half_rhythm"><div>PT, OT</div></li></ul>
|
|
</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Ocular anomalies</b>
|
|
</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mgmt per ophthalmologist</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Renal malformations</b>
|
|
</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mgmt per nephrologist &/or urologist</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Genital anomalies</b>
|
|
</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mgmt per gynecologist or urologist</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Hypothyroidism</b>
|
|
</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment per endocrinologist</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Hearing loss</b>
|
|
</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hearing aids may be helpful; per otolaryngologist.</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Community hearing services through early intervention or school district</td></tr><tr><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Cardiac anomalies</b>
|
|
</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment per cardiologist & surgery</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Nutrition</b>
|
|
</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Supplemental feeding as needed by nasogastric tube or gastrostomy</div></li><li class="half_rhythm"><div>Vitamin D supplementation</div></li></ul>
|
|
</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low threshold for clinical feeding eval if clinical signs or symptoms of dysphagia</td></tr><tr><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Development</b>
|
|
</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early intervention for DDs; individualized education plan for school-age children; therapies (speech, OT, PT) as needed</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Dermatologic</b>
|
|
<br />
|
|
<b>manifestations</b>
|
|
</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Liberal use of sunscreen & rash guards</div></li><li class="half_rhythm"><div>Treatment per dermatologist</div></li></ul>
|
|
</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Family/Community</b>
|
|
</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Ensure appropriate social work involvement to connect families w/local resources, respite, & support.</div></li><li class="half_rhythm"><div>Coordinate care to manage multiple subspecialty appointments, equipment, medications, & supplies.</div></li></ul>
|
|
</td><td headers="hd_h_fa.T.treatment_of_manifestations_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Ongoing assessment of need for palliative care involvement &/or home nursing</div></li><li class="half_rhythm"><div>Consider involvement in adaptive sports or <a href="https://www.specialolympics.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Special Olympics</a>.</div></li></ul>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">DD = developmental delay; OT = occupational therapy; PT = physical therapy</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobfaTrecommendedsurveillanceforindivi"><div id="fa.T.recommended_surveillance_for_indivi" class="table"><h3><span class="label">Table 7. </span></h3><div class="caption"><p>Recommended Surveillance for Individuals with Fanconi Anemia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1401/table/fa.T.recommended_surveillance_for_indivi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fa.T.recommended_surveillance_for_indivi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency</th></tr></thead><tbody><tr><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Growth</b>
|
|
</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Growth/feeding/nutrition assessment</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">At each visit throughout childhood</td></tr><tr><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Scoliosis</b>
|
|
</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Spine exam</td></tr><tr><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Strabismus/</b>
|
|
<br />
|
|
<b>Cataracts</b>
|
|
</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Exam by ophthalmologist</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At each visit throughout childhood, then annually</td></tr><tr><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Endocrine</b>
|
|
<br />
|
|
<b>manifestations <sup>1</sup></b>
|
|
</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Endocrine eval incl:
|
|
<ul><li class="half_rhythm"><div>TSH & free T4</div></li><li class="half_rhythm"><div>25-hydroxy vitamin D</div></li><li class="half_rhythm"><div>2-hr oral glucose tolerance test, insulin levels</div></li></ul>
|
|
</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Annually</td></tr><tr><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Pubertal stage & hormone levels</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At puberty, then every 2 yrs until puberty complete</td></tr><tr><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Hearing loss</b>
|
|
</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Formal hearing eval</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At diagnosis & serially if exposed to ototoxic medications (e.g., chemotherapy agents)</td></tr><tr><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Development</b>
|
|
</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Developmental assessment</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Annually throughout childhood</td></tr><tr><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Pancytopenia</b>
|
|
</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Blood counts</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Every 3-4 mos while stable & more often as needed <sup>2, 3</sup></td></tr><tr><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Myelodysplasia</b>
|
|
</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Bone marrow aspirate/biopsy to evaluate morphology & cellularity</div></li><li class="half_rhythm"><div>FISH; & cytogenetics to evaluate for emergence of a malignant clone</div></li></ul>
|
|
</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>At least annually (after age 2 yrs)</div></li><li class="half_rhythm"><div>In persons on GCSF, bone marrow aspirate/biopsy every 6 mos, if possible</div></li><li class="half_rhythm"><div>Prompt investigation for hematologic disease progression incl in those who develop Sweet syndrome</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Liver dysfunction</b>
|
|
<br />
|
|
<b>due to androgen</b>
|
|
<br />
|
|
<b>therapy</b>
|
|
</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Liver function tests</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Every 3-6 mos in those receiving androgen therapy</td></tr><tr><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Liver ultrasound exam for androgen-related changes, incl tumors</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Every 6-12 mos in those receiving androgen therapy</td></tr><tr><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Genital tract</b>
|
|
<br />
|
|
<b>cancers</b>
|
|
</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gynecologic assessment for genital lesions</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Annually beginning at age 13</td></tr><tr><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Thorough vulvo-vaginal exam & Pap smear</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Annually beginning at age 18 or w/onset of sexual activity</td></tr><tr><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Suspicious genital tract lesions should be biopsied</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Every 3-6 mos in those w/history of premalignant or malignant lesions</td></tr><tr><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Oral, head, &</b>
|
|
<br />
|
|
<b>neck cancers</b>
|
|
</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Exam by dentist, oral surgeon, or ENT familiar w/FA</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Every 6 mos beginning by age 9-10 yrs</div></li><li class="half_rhythm"><div>Every 2-3 mos in those w/history of premalignant or malignant lesions</div></li></ul>
|
|
</td></tr><tr><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Nasolaryngoscopy</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Annually beginning at age 10 yrs, or w/in first year after HSCT</td></tr><tr><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Eval for esophageal cancer in those w/difficulty or pain w/swallowing</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b>Skin cancers</b>
|
|
</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Eval by dermatologist</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Every 6-12 mos</td></tr><tr><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<b><i>BRCA2-</i>related</b>
|
|
<br />
|
|
<b>FA <sup>4, 5</sup></b>
|
|
</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Abdominal ultrasound, brain MRI</td><td headers="hd_h_fa.T.recommended_surveillance_for_indivi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Annually starting at diagnosis (incl newborns)</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="fa.TF.7.1"><p class="no_margin">For example, hypothyroidism, vitamin D deficiency</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="fa.TF.7.2"><p class="no_margin">Progressively changing blood counts without a potential cause (e.g., acute infection or suppression from medication) require immediate evaluation with a complete blood count and bone marrow examination with FISH and cytogenetics.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3. </dt><dd><div id="fa.TF.7.3"><p class="no_margin">It is important to recognize that rising blood counts can be due to either the development of MDS/AML or, rarely, reversion of a germline pathogenic variant in a stem cell, which repopulates the marrow with normal cells (somatic stem cell mosaicism). These individuals may require immediate HSCT (for MDS/AML) or continued close monitoring with complete blood counts at least every one to two months and a bone marrow examination with cytogenetics every six months.</p></div></dd></dl><dl class="bkr_refwrap"><dt>4. </dt><dd><div id="fa.TF.7.4"><p class="no_margin">Neuroblastomas, brain tumors, kidney tumors</p></div></dd></dl><dl class="bkr_refwrap"><dt>5. </dt><dd><div id="fa.TF.7.5"><p class="no_margin">These cancer surveillance recommendations may be considered for persons with <i>PALB2</i>-related Fanconi anemia in the absence of consensus guidelines.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobfamolgenTA"><div id="fa.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Fanconi Anemia: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1401/table/fa.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fa.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/672" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>BRCA1</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=672" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">17q21<wbr style="display:inline-block"></wbr>​.31</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/P38398" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Breast cancer type 1 susceptibility protein</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.LOVD.nl/BRCA1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">BRCA1 homepage - LOVD</a>
|
|
<br />
|
|
<a href="http://hci-exlovd.hci.utah.edu/home.php?select_db=BRCA1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Database of BRCA1 and BRCA2 sequence variants that have been clinically reclassified by a quantitative integrated evaluation</a>
|
|
<br />
|
|
<a href="https://research.nhgri.nih.gov/bic/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Breast Cancer Information Core (BRCA1)</a>
|
|
<br />
|
|
<a href="https://lovd.nl/BRCA1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">BRCA1 @ ZAC-GGM</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=BRCA1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">BRCA1</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=BRCA1[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">BRCA1</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/675" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>BRCA2</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=675" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">13q13<wbr style="display:inline-block"></wbr>​.1</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/P51587" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Breast cancer type 2 susceptibility protein</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.LOVD.nl/BRCA2" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">BRCA2 homepage - LOVD</a>
|
|
<br />
|
|
<a href="http://hci-exlovd.hci.utah.edu/home.php?select_db=BRCA2" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Database of BRCA1 and BRCA2 sequence variants that have been clinically reclassified using a quantitative integrated evaluation</a>
|
|
<br />
|
|
<a href="https://research.nhgri.nih.gov/bic/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Breast Cancer Information Core (BRCA2)</a>
|
|
<br />
|
|
<a href="http://www.rockefeller.edu/fanconi/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi Anaemia Mutation Database (FANCD1 - BRCA2)</a>
|
|
<br />
|
|
<a href="https://lovd.nl/BRCA2" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">BRCA2 @ ZAC-GGM</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=BRCA2" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">BRCA2</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=BRCA2[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">BRCA2</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/83990" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>BRIP1</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=83990" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">17q23<wbr style="display:inline-block"></wbr>​.2</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/Q9BX63" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi anemia group J protein</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.LOVD.nl/BRIP1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">BRIP1 @ LOVD</a>
|
|
<br />
|
|
<a href="https://www.lovd.nl/FANCJ" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi Anaemia Mutation Database (FANCJ - BRIP1)</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=BRIP1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">BRIP1</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=BRIP1[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">BRIP1</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/2072" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>ERCC4</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=2072" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">16p13<wbr style="display:inline-block"></wbr>​.12</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/Q92889" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">DNA repair endonuclease XPF</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://databases.lovd.nl/shared/genes/ERCC4" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">ERCC4 database</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ERCC4" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">ERCC4</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ERCC4[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">ERCC4</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/80233" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>FAAP100</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=80233" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">17q25<wbr style="display:inline-block"></wbr>​.3</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/Q0VG06" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi anemia core complex-associated protein 100</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FAAP100" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FAAP100</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FAAP100[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FAAP100</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/2175" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>FANCA</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=2175" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">16q24<wbr style="display:inline-block"></wbr>​.3</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/O15360" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi anemia group A protein</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.lovd.nl/FANCA" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi Anemia Mutation Database (FANCA)</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FANCA" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCA</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FANCA[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCA</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/2187" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>FANCB</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=2187" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Xp22<wbr style="display:inline-block"></wbr>​.2</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/Q8NB91" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi anemia group B protein</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.LOVD.nl/FANCB" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCB @ LOVD</a>
|
|
<br />
|
|
<a href="https://www.lovd.nl/FANCB" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi Anaemia Mutation Database (FANCB)</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FANCB" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCB</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FANCB[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCB</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/2176" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>FANCC</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=2176" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">9q22<wbr style="display:inline-block"></wbr>​.32</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/Q00597" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi anemia group C protein</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://databases.lovd.nl/shared/genes/FANCC" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi Anemia Mutation Database (FANCC)</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FANCC" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCC</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FANCC[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCC</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/2177" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>FANCD2</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=2177" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">3p25<wbr style="display:inline-block"></wbr>​.3</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/Q9BXW9" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi anemia group D2 protein</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.lovd.nl/FANCD2" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi Anaemia Mutation Database (FANCD2)</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FANCD2" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCD2</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FANCD2[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCD2</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/2178" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>FANCE</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=2178" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">6p21<wbr style="display:inline-block"></wbr>​.31</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/Q9HB96" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi anemia group E protein</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.lovd.nl/FANCE" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi Anaemia Mutation Database (FANCE)</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FANCE" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCE</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FANCE[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCE</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/2188" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>FANCF</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=2188" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">11p14<wbr style="display:inline-block"></wbr>​.3</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/Q9NPI8" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi anemia group F protein</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.lovd.nl/FANCF" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi Anaemia Mutation Database (FANCF)</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FANCF" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCF</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FANCF[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCF</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/2189" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>FANCG</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=2189" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">9p13<wbr style="display:inline-block"></wbr>​.3</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/O15287" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi anemia group G protein</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.lovd.nl/FANCG" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi Anaemia Mutation Database (FANCG)</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FANCG" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCG</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FANCG[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCG</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/55215" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>FANCI</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=55215" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">15q26<wbr style="display:inline-block"></wbr>​.1</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/Q9NVI1" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi anemia group I protein</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.lovd.nl/FANCI" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi Anemia Mutation Database (FANCI)</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FANCI" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCI</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FANCI[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCI</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/55120" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>FANCL</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=55120" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">2p16<wbr style="display:inline-block"></wbr>​.1</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/Q9NW38" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">E3 ubiquitin-protein ligase FANCL</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.lovd.nl/FANCL" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi Anaemia Mutation Database (FANCL)</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FANCL" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCL</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FANCL[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCL</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/57697" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>FANCM</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=57697" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">14q21<wbr style="display:inline-block"></wbr>​.2</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/Q8IYD8" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi anemia group M protein</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.LOVD.nl/FANCM" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Fanconi Anaemia Mutation Database (FANCM)</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FANCM" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCM</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FANCM[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">FANCM</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/10459" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>MAD2L2</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=10459" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">1p36<wbr style="display:inline-block"></wbr>​.22</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/Q9UI95" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Mitotic spindle assembly checkpoint protein MAD2B</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=MAD2L2" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">MAD2L2</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=MAD2L2[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">MAD2L2</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/79728" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>PALB2</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=79728" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">16p12<wbr style="display:inline-block"></wbr>​.2</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/Q86YC2" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Partner and localizer of BRCA2</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.lovd.nl/PALB2" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PALB2 database</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=PALB2" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PALB2</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=PALB2[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PALB2</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/5888" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>RAD51</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=5888" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">15q15<wbr style="display:inline-block"></wbr>​.1</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/Q06609" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">DNA repair protein RAD51 homolog 1</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://databases.lovd.nl/shared/genes/RAD51" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">RAD51 database</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=RAD51" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">RAD51</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=RAD51[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">RAD51</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/5889" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>RAD51C</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=5889" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">17q22</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/O43502" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">DNA repair protein RAD51 homolog 3</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.LOVD.nl/RAD51C" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">RAD51C @ LOVD</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=RAD51C" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">RAD51C</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=RAD51C[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">RAD51C</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/55159" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>RFWD3</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=55159" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">16q23<wbr style="display:inline-block"></wbr>​.1</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/Q6PCD5" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">E3 ubiquitin-protein ligase RFWD3</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=RFWD3" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">RFWD3</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=RFWD3[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">RFWD3</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/84464" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>SLX4</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=84464" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">16p13<wbr style="display:inline-block"></wbr>​.3</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/Q8IY92" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Structure-specific endonuclease subunit SLX4</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.LOVD.nl/SLX4" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">SLX4 @ LOVD</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SLX4" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">SLX4</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SLX4[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">SLX4</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/29089" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>UBE2T</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=29089" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">1q32<wbr style="display:inline-block"></wbr>​.1</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/Q9NPD8" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Ubiquitin-conjugating enzyme E2 T</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=UBE2T" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">UBE2T</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=UBE2T[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">UBE2T</a>
|
|
</td></tr><tr><td headers="hd_b_fa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="/gene/7516" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=gene">
|
|
<i>XRCC2</i>
|
|
</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&acc=7516" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">7q36<wbr style="display:inline-block"></wbr>​.1</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.uniprot.org/uniprot/O43543" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">DNA repair protein XRCC2</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.lovd.nl/XRCC2" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">XRCC2 @ LOVD</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=XRCC2" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">XRCC2</a>
|
|
</td><td headers="hd_b_fa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=XRCC2[gene]" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">XRCC2</a>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div id="fa.TFA.1"><p class="no_margin">Data are compiled from the following standard references: gene from
|
|
<a href="http://www.genenames.org/index.html" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">HGNC</a>;
|
|
chromosome locus from
|
|
<a href="http://www.omim.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">OMIM</a>;
|
|
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">UniProt</a>.
|
|
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
|
|
<a href="/books/n/gene/app1/?report=reader">here</a>.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobfamolgenTB"><div id="fa.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Fanconi Anemia (<a href="/omim/113705,133520,179617,227645,227646,227650,300514,300515,600185,600375,600901,602774,602956,603467,604094,605724,605882,607139,608111,609053,609054,609644,610355,610538,610832,611301,611360,613278,613390,613897,613899,613951,613976,613984,614082,614083,614087,614151,615272,616435,617243,617244,617247,617784,617883" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1401/table/fa.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fa.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/113705" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">113705</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BRCA1 DNA REPAIR-ASSOCIATED PROTEIN; BRCA1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/133520" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">133520</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ERCC EXCISION REPAIR 4, ENDONUCLEASE CATALYTIC SUBUNIT; ERCC4</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/179617" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">179617</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RAD51 RECOMBINASE; RAD51</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/227645" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">227645</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP C; FANCC</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/227646" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">227646</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP D2; FANCD2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/227650" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">227650</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP A; FANCA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/300514" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">300514</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP B; FANCB</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/300515" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">300515</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCB GENE; FANCB</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/600185" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">600185</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BRCA2 DNA REPAIR-ASSOCIATED PROTEIN; BRCA2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/600375" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">600375</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">X-RAY REPAIR CROSS COMPLEMENTING 2; XRCC2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/600901" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">600901</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP E; FANCE</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/602774" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">602774</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RAD51 PARALOG C; RAD51C</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/602956" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">602956</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCG GENE; FANCG</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/603467" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">603467</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP F; FANCF</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/604094" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">604094</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MITOTIC ARREST-DEFICIENT 2 LIKE 2; MAD2L2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/605724" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">605724</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP D1; FANCD1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/605882" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">605882</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BRCA1-INTERACTING PROTEIN 1; BRIP1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/607139" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">607139</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCA GENE; FANCA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/608111" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">608111</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCL GENE; FANCL</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/609053" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">609053</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP I; FANCI</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/609054" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">609054</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP J; FANCJ</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/609644" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">609644</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCM GENE; FANCM</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/610355" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">610355</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PARTNER AND LOCALIZER OF BRCA2; PALB2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/610538" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">610538</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">UBIQUITIN-CONJUGATING ENZYME E2 T; UBE2T</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/610832" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">610832</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP N; FANCN</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/611301" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">611301</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA-ASSOCIATED PROTEIN, 100-KD SUBUNIT; FAAP100</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/611360" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">611360</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCI GENE; FANCI</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/613278" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">613278</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SLX4 STRUCTURE-SPECIFIC ENDONUCLEASE SUBUNIT; SLX4</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/613390" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">613390</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP O; FANCO</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/613897" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">613897</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCF GENE; FANCF</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/613899" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">613899</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCC GENE; FANCC</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/613951" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">613951</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP P; FANCP</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/613976" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">613976</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCE GENE; FANCE</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/613984" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">613984</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCD2 GENE; FANCD2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/614082" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">614082</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP G; FANCG</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/614083" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">614083</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP L; FANCL</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/614087" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">614087</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP M; FANCM</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/614151" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">614151</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RING FINGER AND WD REPEAT DOMAINS-CONTAINING PROTEIN 3; RFWD3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/615272" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">615272</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP Q; FANCQ</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/616435" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">616435</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP T; FANCT</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/617243" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">617243</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP V; FANCV</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/617244" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">617244</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP R; FANCR</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/617247" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">617247</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP U; FANCU</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/617784" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">617784</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP W; FANCW</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="/omim/617883" ref="pagearea=body&targetsite=entrez&targetcat=term&targettype=omim">617883</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FANCONI ANEMIA, COMPLEMENTATION GROUP S; FANCS</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobfaTfanconianemianotablepathogenicv"><div id="fa.T.fanconi_anemia_notable_pathogenic_v" class="table"><h3><span class="label">Table 8. </span></h3><div class="caption"><p>Fanconi Anemia: Notable Pathogenic Variants by Gene</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1401/table/fa.T.fanconi_anemia_notable_pathogenic_v/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__fa.T.fanconi_anemia_notable_pathogenic_v_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene <sup>1</sup></th><th id="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference<br />Sequences</th><th id="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change (Alias <sup>2</sup>)</th><th id="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein<br />Change</th><th id="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment [Reference]</th></tr></thead><tbody><tr><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>FANCA</i>
|
|
</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_2" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000135.4" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NM_000135<wbr style="display:inline-block"></wbr>​.4</a>
|
|
<br />
|
|
<a href="https://www.ncbi.nlm.nih.gov/protein/66880553" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NP_000126<wbr style="display:inline-block"></wbr>​.2</a>
|
|
</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1115_1118delTTGG</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val372AlafsTer42</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Common in northern Europeans</td></tr><tr><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.2738A>C</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.His913Pro</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_5" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">Assoc w/slower hematologic disease progression [<a class="bibr" href="#fa.REF.bottega.2018.417" rid="fa.REF.bottega.2018.417">Bottega et al 2018</a>]</td></tr><tr><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.2852G>A</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg951Gln</td></tr><tr><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.2851C>T</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg951Trp</td></tr><tr><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_1" rowspan="6" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<i>FANCC</i>
|
|
</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&id=NM_000136.3" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NM_000136<wbr style="display:inline-block"></wbr>​.3</a>
|
|
</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.456+4A>T<br />(IVS4+4A>T)</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Common in Ashkenazi Jewish; also reported in a Japanese cohort <sup>3</sup></td></tr><tr><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_2" rowspan="2" colspan="1" scope="row" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&id=NM_000136.3" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NM_000136<wbr style="display:inline-block"></wbr>​.3</a>
|
|
<br />
|
|
<a href="https://www.ncbi.nlm.nih.gov/protein/56118236" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NP_000127<wbr style="display:inline-block"></wbr>​.2</a>
|
|
</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.37C>T</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln13Ter</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Common in northern Europeans <sup>3</sup></td></tr><tr><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.67delG<br />(322delG)</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp23IlefsTer23</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Common in northern Europeans & southern Italy <sup>3</sup></td></tr><tr><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&id=NM_000136.3" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NM_000136<wbr style="display:inline-block"></wbr>​.3</a>
|
|
</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.165+1G>T</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See <a href="#fa.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>.</td></tr><tr><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_2" rowspan="2" colspan="1" scope="row" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&id=NM_000136.3" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NM_000136<wbr style="display:inline-block"></wbr>​.3</a>
|
|
<br />
|
|
<a href="https://www.ncbi.nlm.nih.gov/protein/56118236" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NP_000127<wbr style="display:inline-block"></wbr>​.2</a>
|
|
</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1642C>T</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg548Ter</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Common in northern Europeans & southern Italy <sup>3</sup></td></tr><tr><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1661T>C</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu554Pro</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See <a href="#fa.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>.</td></tr><tr><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<p>
|
|
<i>FANCG</i>
|
|
</p>
|
|
</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/nuccore/4759335" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NM_004629<wbr style="display:inline-block"></wbr>​.2</a>
|
|
</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.307+1G>C<br />(IVS3+1G>C)</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Common in Koreans & Japanese</td></tr><tr><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.925-2A>G<br />(IVS8-2A>G)</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Common in Brazil & northern Europeans</td></tr><tr><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_2" rowspan="2" colspan="1" scope="row" style="text-align:left;vertical-align:middle;">
|
|
<a href="https://www.ncbi.nlm.nih.gov/nuccore/4759335" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NM_004629<wbr style="display:inline-block"></wbr>​.2</a>
|
|
<br />
|
|
<a href="https://www.ncbi.nlm.nih.gov/protein/4759336" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NP_004620<wbr style="display:inline-block"></wbr>​.1</a>
|
|
</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1183_1192del10<br />(1184-1194del)</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu395TrpfsTer5</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<a class="bibr" href="#fa.REF.demuth.2000.861" rid="fa.REF.demuth.2000.861">Demuth et al [2000]</a>
|
|
</td></tr><tr><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1480+1G>C<br />(IVS11+1G>C)</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp599ProfsTer49</td><td headers="hd_h_fa.T.fanconi_anemia_notable_pathogenic_v_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Common in French Canadians & northern Europeans [<a class="bibr" href="#fa.REF.auerbach.2003.158" rid="fa.REF.auerbach.2003.158">Auerbach et al 2003</a>]</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="https://varnomen.hgvs.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/?report=reader">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl><dl class="bkr_refwrap"><dt>1. </dt><dd><div id="fa.TF.8.1"><p class="no_margin">Genes from <a href="/books/NBK1401/table/fa.T.molecular_genetic_testing_used_in_f/?report=objectonly" target="object" rid-ob="figobfaTmoleculargenetictestingusedinf">Table 1</a> in alphabetic order</p></div></dd></dl><dl class="bkr_refwrap"><dt>2. </dt><dd><div id="fa.TF.8.2"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd></dl><dl class="bkr_refwrap"><dt>3. </dt><dd><div id="fa.TF.8.3"><p class="no_margin">See <a href="#fa.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>.</p></div></dd></dl></dl></div></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script><script type="text/javascript">if (typeof (jQuery) != 'undefined') { (function ($) { $(function () { var min = Math.ceil(1); var max = Math.floor(100000); var randomNum = Math.floor(Math.random() * (max - min)) + min; var surveyUrl = "/projects/Gene/portal/surveys/seqdbui-survey.js?rando=" + randomNum.toString(); $.getScript(surveyUrl, function () { try { ncbi.seqDbUISurvey.init(); } catch (err) { console.info(err); } }).fail(function (jqxhr, settings, exception) { console.info('Cannot load survey script', jqxhr); });; }); })(jQuery); };</script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal104 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|